Utah State University

DigitalCommons@USU
All Graduate Theses and Dissertations

Graduate Studies

5-2015

DNA Methylation in Lung Tissues of Mouse Offspring Exposed In
utero to Polycyclic Aromatic Hydrocarbons
Trevor J. Fish
Utah State University

Follow this and additional works at: https://digitalcommons.usu.edu/etd
Part of the Biochemistry Commons

Recommended Citation
Fish, Trevor J., "DNA Methylation in Lung Tissues of Mouse Offspring Exposed In utero to Polycyclic
Aromatic Hydrocarbons" (2015). All Graduate Theses and Dissertations. 4578.
https://digitalcommons.usu.edu/etd/4578

This Thesis is brought to you for free and open access by
the Graduate Studies at DigitalCommons@USU. It has
been accepted for inclusion in All Graduate Theses and
Dissertations by an authorized administrator of
DigitalCommons@USU. For more information, please
contact digitalcommons@usu.edu.

DNA METHYLATION IN LUNG TISSUES OF MOUSE OFFSPRING EXPOSED
IN UTERO TO POLYCYCLIC AROMATIC HYDROCARBONS
by
Trevor J Fish
A thesis submitted in partial fulfillment
of the requirements for the degree
of
MASTER OF SCIENCE
in
Toxicology
Approved:

Abby D. Benninghoff, Ph.D.
Major Professor

Aaron L. Olsen, D.V.M., Ph.D.
Committee Member

Roger A. Coulombe Jr., Ph.D.
Committee Member

S. Clay Isom, Ph.D.
Committee Member

Korry J. Hintze, Ph.D.
Committee Member

Dirk K. Vanderwall, D.V.M., Ph.D.
ADVS Department Head

Mark R. McLellan, Ph.D.
Vice President for Research and
Dean of the School of Graduate Studies
UTAH STATE UNIVERSITY
Logan, Utah
2015

ii

Copyright © Trevor J Fish 2015
All Rights Reserved

iii
ABSTRACT
DNA Methylation in Lung Tissues of Mouse Offspring Exposed
In Utero to Polycyclic Aromatic Hydrocarbons
by
Trevor J Fish, Master of Science
Utah State University, 2015
Major Professor: Dr. Abby D. Benninghoff
Department: Animal, Dairy and Veterinary Sciences
Polycyclic aromatic hydrocarbons (PAHs) comprise an important class of
environmental pollutants that are known to cause lung cancer in animals and are
suspected lung carcinogens in humans. PAHs are also known to cause cancer in offspring
when provided to a pregnant mouse. Moreover, evidence from cell-based studies points
to PAHs as modulators of the epigenome, that is modifications to DNA structure that
control the expression of genes. The objective of this thesis research was to determine the
impact of transplacental exposure of PAHs on the epigenome of fetal and adult lung
tissues in offspring exposed to either dibenzo[def,p]chrysene (DBC) or benzo[a]pyrene
(BaP) throughout gestation and lactation. Lung tumor incidence in 45-week old mice
initiated with BaP was 30%, much lower than that of the DBC-exposed offspring at
100%. The spontaneous lung tumor rate was 9% in control offspring at 45-weeks.
Promoter methylation for Cdkn2a, Rarb, Dapk1 and Mgmt genes was assessed by
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bisulfite sequencing. Laser capture microdissection was employed to assess the
methylation of these selected tumor suppressor genes during the process of tumor
progression. Analysis of methylation for the Cdkn2a promoter revealed a localized region
of moderate methylation associated with CpG sites 27 to 30 in all samples evaluated. No
differences in methylation were apparent for the other target genes. Genome-wide
methylation of lung tumors in adult offspring was determined using the NimbleGen DNA
Methylation array. The genome-wide assessment of CpG island promoter methylation
revealed distinct patterns of methylation associated with normal and adenocarcinoma
lung tissues. Furthermore, gene ontology analysis revealed differences in the biological
functions represented by the methylated genes in normal lung tissues compared to tumor
tissues. Altogether, the research presented here identified several new target genes of
interest for future studies investigating the epigenetics of PAH-initiated lung cancer. This
work also provided new knowledge that transplacental exposure to PAHs can lead to
distinct DNA methylation profiles in lung tumors in adult offspring.
(169 pages)
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PUBLIC ABSTRACT
DNA Methylation in Lung Tissues of Mouse Offspring Exposed
In Utero to Polycyclic Aromatic Hydrocarbons
by
Trevor J Fish, Master of Science
Utah State University, 2015
Major Professor: Dr. Abby D. Benninghoff
Department: Animal, Dairy and Veterinary Sciences
Polycyclic aromatic hydrocarbons (PAHs) comprise an important class of
environmental pollutants that are known to cause lung cancer in animals and suspected
lung carcinogens in humans. PAHs are also known to cause cancer in offspring when
provided to a pregnant mouse. Some evidence from cell-based studies points to PAHs as
modulators of the epigenome, that is modifications to DNA structure that control the
expression of genes. Inappropriate changes to the epigenome and consequently
expression of cancer-critical genes are often characteristic of cancer cells. The objective
of this thesis research was to determine the impact of transplacental exposure to two
model PAHs on the epigenome of fetal and adult lung tissues in offspring. Specifically,
we measured patterns of methylation of DNA, a type of epigenetic mark, in different
types of lung tissue to assess changes in the epigenome associated with development of
lung cancer. Two strategies were employed: 1) a targeted approach using ultra-deep
bisulfite sequencing to precisely measure the specific pattern of methylated sites in the
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promoter regulatory region for several tumor suppressor genes, including Cdkn2a, Rarb,
Dapk1 and Mgmt; and 2) a broad, genome-wide approach using a microarray covering all
regulatory promoter regions in the entire mouse genome. Our first approach did not yield
any marked differences in methylation patterns for any of the target genes for lung tissues
obtained at birth or at various ages up to 45 weeks, nor according to the type of tissue
(normal, pre-neoplastic, tumor). However, the genome-wide approach did yield specific
patterns of methylation in lung tumors, including distinct profiles associated with lung
tumor tissue from PAH-exposed animals that were substantially different from normal
lung tissue in control animals. Altogether, the research presented here identified several
new target genes of interest for future studies investigating the epigenetics of PAHinitiated lung cancer. This work also provided new knowledge that exposure to PAHs can
lead to distinct DNA methylation profiles in lung tumors in adult offspring.
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INTRODUCTION
Statistics on Lung Cancer
Lung cancer is the leading cause of cancer death worldwide and is the most
common cancer in the world, with estimated deaths totaling 1,590,000 in 2012. New
cases were estimated to be 1.8 million in 2012, 58% of which occurred in economically
less-developed regions of the world (Fig. 1) (Ferlay, et al., 2013). For the United States,

FIG. 1. Worldwide lung cancer incidence and mortality. (A) Estimated number of
cases for the most common cancers worldwide in 2012. (B) Bars represent the
estimated number of new lung cancer cases and the estimated number of lung cancer
deaths as a percentage of all cancers (excluding non-melanoma skin cancers) for male
or females in developed (dark blue) or developing (light blue) nations. Numbers above
the bar represent the number of cases or deaths. (C) World map depicting incidence of
lung cancer by nation for both males and females (values shown are the agestandardized rate per 100,000 people). Source data were obtained from the
GLOBOCAN 2012 database (Ferlay, et al., 2013).
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an estimated 224,210 new cases of lung cancer were documented in 2014, a number that
accounts for about 13% of all cancer diagnoses that year. The estimated new cases of
lung cancer for both males and females rank second after prostate cancer for males and
breast cancer for females. The rate of lung cancer incidence in men started to decline in
the mid-1980s, whereas a decline was evident for women in the mid-2000s (American
Cancer Society, 2015). Estimated deaths in 2014 due to lung cancer are higher than the
combined total for prostate cancer, breast cancer, and colorectal cancer (Siegel et al.,
2014). Lung cancer is a deadly disease with a poor five-year survival rate of only 17%. In
addition, roughly half of lung cancer patients die within one year of being diagnosed
(Howlader N, 2015; Siegel, et al., 2014).
The two main types of lung cancer are small cell lung cancer (13% of cases) and
non-small cell lung cancer (83%), with non-small cell lung cancer (NSCLC) being
further classified within three main subtypes: adenocarcinoma, squamous-cell carcinoma
and large-cell carcinoma (American Cancer Society, 2015). Adenocarcinoma is usually
found in peripheral locations of the lung but also can be observed centrally in a main
bronchus. Squamous-cell lung carcinoma tends to be found near the middle of the lungs,
near a bronchus. Large-cell carcinoma can appear in any part of the lung.
Adenocarcinoma is the predominant form of lung cancer diagnosed in neversmokers, whereas smokers develop all major histological types of lung cancer
(MacKinnon et al., 2010). The diagnosis and staging of lung cancer are often performed
simultaneously, and some of the common tests and procedures used include physical
exam, chest x-ray, CT scan, biopsy, sputum cytology and immunohistochemistry.
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NSCLC progresses through several stages as it develops from simple abnormal cells to
full adenocarcinoma of the lung. Briefly, in stage 0, also called carcinoma in situ,
abnormal cells are found in the lining of airways. In stage I patients, the cancer is
localized to the lungs but has not spread to any lymph nodes outside the lung. Stage II is
typified by spread of the cancer to nearby lymph nodes. Stage III is subdivided into IIIA
and IIIB depending upon the location of the tumor and the infiltrated lymph nodes. Stage
IV is the most advanced stage of lung cancer in which cancer has spread to both lungs
and metastasized to other organs, such as the brain, liver, adrenal glands, kidneys or bone
(National Cancer Institute, 2015). Metastases to these critical organs account for the
majority of lung cancer deaths (Nichols et al., 2012).
Lung cancer incidence and mortality vary with respect to race. The Centers for
Disease Control and Prevention (CDC) reported that among men, black men had the
highest rates for lung cancer incidence and mortality, followed by white men and then by
men representing other ethnic groups. Conversely, white women had the highest
incidence and mortality rates, followed by black women (Centers for Disease Control and
Prevention, 2014). As with many cancers, risk of developing lung cancer increases with
age.
Today, lung cancer risk typically is greater in men than in women, and the higher
risk apparent for men has been attributed to smoking habits, environment and lifestyle
choices (Freedman et al., 2008; Sun et al., 2007). The issue of gender in lung cancer risk
has been debated since the early 1990s, at which time reports from case control studies
showed higher odds ratio in women than men (Osann et al., 1993; Risch et al., 1993;
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Zang and Wynder, 1996). Cohort studies consistently found higher lung cancer death
rates in men than women, both in the presence (Thun et al., 2002) and absence (Thun et
al., 2008; Thun et al., 2006) of smoking. However, this pattern did not appear to be
consistent when considering newly diagnosed cases (Bach et al., 2003). Some researchers
have hypothesized that, among smokers, women may have higher risk of developing lung
cancer than men but lower risk of dying from the disease (Henschke and Miettinen, 2004;
Henschke et al., 2006). Additionally, Wakelee, et al. (2007) documented that lung cancer
incidence rates were higher in women than men among never-smokers. The accumulated
evidence supports the notion that lung cancer risk is not consistent for men and women.
Further research is needed to elucidate the gender differences in respect to lung cancer
risk.
Lung cancer risk is also elevated among people with genetic susceptibility, such
as the carriers of tumor protein 53 (TP53) germline sequence variations, often as a
hereditary feature (Molina et al., 2008). The tumor suppressor gene TP53 plays a vital
role in the process of apoptosis and is an important stress response molecule that is
activated in response to diverse intrinsic and extrinsic signals (Rozan and El-Deiry,
2007). In addition, there is a linear relationship between TP53 mutation risk and tobacco
consumption, as mutations of this gene are less frequent in never-smokers than in those
who smoke (Hernandez-Boussard and Hainaut, 1998; Le Calvez et al., 2005). Increased
lung cancer risk is also associated with mutations in other genes, including epidermal
growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and kirsten rat
sarcoma viral oncogene homolog (KRAS) (Couraud et al., 2012; Pendharkar et al., 2013).
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EGFR is responsible for a cascade of biological effects in normal cells and is often
involved in cancer cell biology by activating tumorigenic processes, such as cell
proliferation and angiogenesis (Schlessinger, 2002). ALK is a receptor tyrosine kinase
and the EML4 (echinoderm microtubule–associated protein–like 4)-ALK fusion is the
most common ALK rearrangement in NSCLC (Choi et al., 2008; Pendharkar, et al.,
2013). This receptor has gained clinical relevance and importance as a therapeutic target
for NSCLC. KRAS is involved primarily in regulating cell division as part of the
RAS/mitogen-activated protein kinase (MAPK) signaling pathway. KRAS mutations are
found in 20-30% of NSCLC cases, predominately in adenocarcinomas (Couraud, et al.,
2012). Changes in these and other genes may make some lung cancers more likely to
grow and metastasize.
Cigarette smoking is by far the most important risk factor for lung cancer. About
90% of lung cancer cases have been attributed to this behavior, and risk of lung cancer
increases with both quantity and duration of smoking (Centers for Disease Control and
Prevention, 2014). Besides smoking cigarettes, several other environmental risk factors
may increase the chance of developing lung cancer. Exposure to radon gas released from
soil and building materials is estimated to be the second leading cause of lung cancer in
Europe and North America (American Cancer Society, 2015). Other risk factors include
environmental or occupational exposure to asbestos, silica, certain metals (cadmium,
nickel, chromium, arsenic), radiation, air pollution, soot, tar and diesel exhaust
(American Cancer Society, 2015; Centers for Disease Control and Prevention, 2014;
Molina, et al., 2008; Siegel, et al., 2014). Never-smokers account for 10-15% of all lung

6
cancer cases, and these are typically associated with combination of genetic factors and
exposure to other forms of air pollution (Thun, et al., 2008). Some researchers regard
lung cancer in never-smokers as a different disease, which would then be ranked as the
seventh leading cause of cancer death worldwide (Sun, et al., 2007; Wakelee, et al.,
2007).
Polycyclic Aromatic Hydrocarbons
Polycyclic Aromatic Hydrocarbons (PAHs) comprise a large class of structurally
diverse organic molecules comprised of two or more fused aromatic rings (Fig. 2). PAHs
are non-polar, lipophilic, organic compounds that do not contain any heteroatoms. Fully
aromatic PAHs are generally planar with a molecular thickness of 3.7 Å (Harvey, 1991).

FIG. 2. Chemical structures for example polycyclic aromatic hydrocarbons.
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PAHs present in the environment usually originate from anthropogenic sources and are
formed during incomplete combustion of organic matter. Shen et al. (2013) reported the
major global atmospheric emissions of PAHs in 2007 to be residential/commercial
biomass burning (60.5%), open-field biomass burning (agricultural waste burning,
deforestation, and wildfire, 13.6%), and motor vehicles (12.8%). Natural events such as
forest fires, natural oil seeps and volcanic activity also release PAHs into the atmosphere.
Thermal decomposition of nearly any organic material may lead to the formation of
PAHs. Other important anthropogenic sources of PAHs include cigarette smoke,
industrial coke production, asphalt roads, coal tar, incineration, industrial power
generation and hazardous waste sites (Luch, 2005). Benzo[a]pyrene (BaP) is one of the
most common PAHs detected in the environment; annual production of BaP was
estimated to range between 300 and 1,300 metric tons. An estimated 11,000 metric tons
of all PAHs were released to the atmosphere on an annual basis (ATSDR, 1995).
PAHs are widely distributed in human food as a result of contamination from air,
soil and water, or as a byproduct of certain food preparation processes (e.g., frying,
grilling, smoking or charbroiling fish or meat) (Phillips, 1999). Amounts of PAHs present
in food are highly variable, but can be as high as parts per billion, depending on the food
item and the way that it is prepared. For non-smokers, food is considered one of the main
sources of human PAH exposure in the general public. The average total daily intake of
PAHs by a member of the general population has been estimated to be 0.207 µg/day from
air, 0.027 µg/day from water, and 0.16 to 1.6 µg/day from food (ATSDR, 1995). Tobacco
smoke is one of the most important sources of PAH exposure indoors. Cigarettes contain
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72 known human or animal carcinogens, including BaP at 13.5 ng per cigarette and the
most abundant carcinogen, N’-nitrosonornicotine (NNN) at 70.5 ng per cigarette (Hecht,
2011).
More than two centuries ago, Percivall Pott (1775), a surgeon in St. Bartholomew’s Hospital in London, England, described the occurrence of scrotal cancer in
chimney sweeps and traced it to the contamination of the skin by soot, now known to be a
major source of PAHs. Nearly 100 years later, Volkmann and Bell described several
cases of scrotal skin tumors among workers in the German and Scottish paraffin industry
(Bell, 1876; Volkmann, 1874). The first official acknowledgment that cancer of any
cutaneous site could be caused by pitch, tar or tarry substances was made in an addendum
to the Workmen’s Compensation Act of Great Britain in 1907, which stated that “scrotal
epithelioma occurring in chimney sweeps and epitheliomattous cancer or ulceration of
the skin occurring in the handling or use of pitch, tar or tarry compound” (Henry, 1947).
Following these observations, researchers embarked on a series of systematic
studies to address the potential for PAHs to cause cancer. Yamagiwa and Ichikawa
(1918) were successful in achieving the production of malignant epithelial tumors by
repetitive application of coal tar to the ear skin of rabbits. Further evidence that PAHs
induce skin tumors in animals was obtained using ethereal extracts of soot (Passey and
Carter-Braine, 1925). Around 1930, several researchers worked on the isolation and
synthesis of hydrocarbons from coal tar (Cook et al., 1933; Hieger, 1930; Kennaway,
1930; Kennaway and Hieger, 1930). During this time, BaP was first isolated and
identified from coal tar (Cook, et al., 1933). Boyland and Levi (1935) discovered urinary
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metabolites of small PAHs, such as anthracene and suggested that toxic hydrocarbons
might either be converted into more active metabolites or be detoxified by conversion
into other compounds.
The two PAHs, dibenzo[def,p]chrysene (DBC) and BaP have been classified by
the International Agency for Research on Cancer (IARC) as group 2A (probably
carcinogenic to humans) and group 1 (carcinogenic to humans), respectively. The IARC
reported that BaP produced tumors in all species tested (mouse, rat, hamster, guinea-pig,
rabbit, duck, newt, monkey) for which data were reported following exposure by many
different routes (oral, dermal, inhalation, intratracheal, intrabronchial, subcutaneous,
intraperitoneal, intravenous) yielding many different tumor types (cancer of the liver,
stomach, tongue, esophagus, lung, skin, breast, lymphoid and abdomen) (reviewed in
(International Agency for Research on Cancer, 2012). DBC has been reported by the
IARC to produce tumors in mice, rats, hamsters and fish with cancers of the skin, ovary,
testicle, liver, stomach, lung, lymphoid and breast (reviewed in International Agency for
Research on Cancer, 2010). With DBC as the most mutagenic and carcinogenic of all the
PAHs (Bostrom et al., 2002) and BaP as the most extensively studied, these two PAHs
are representative prototypes for environmental PAH toxins.
Women are unavoidably exposed to environmental pollutants during pregnancy.
In non-occupational settings, most PAH exposures for non-smoking persons are
associated with diet. The developing fetus and neonate are especially sensitive to
chemical insults due to increased rates of cell division and underdeveloped detoxification
and elimination pathways (Burdge and Lillycrop, 2010; Perera et al., 1999). Cancer risk

10
in adult life may be affected by transplacental exposure to environmental chemicals,
resulting from greater relative DNA damage and a more rapid frequency of mutations
during fetal development (Whyatt et al., 2001). Evidence suggests that many carcinogens
are bioactive when administered transplacentally or perinatally and could be linked with
childhood and adult cancers (Anderson, 2004; Anderson et al., 2000; Flower et al., 2004;
Jensen et al., 2004; Lightfoot and Roman, 2004; Ma et al., 2002; Perera et al., 2005;
Perera et al., 2004; Sandler et al., 1985; Sasco and Vainio, 1999; Tang et al., 2006;
Whyatt et al., 2000; Zahm and Ward, 1998). Exposure during gestation and throughout
breast feeding represents a significant portion of lifetime exposure to PAHs (Somogyi
and Beck, 1993).
Studies using animal models have provided further evidence that transplacental
exposure to environmental pollutants including PAHs, cigarette smoke, arsenic and
benzene can induce carcinogenesis in offspring (Badham et al., 2010; Nicolov and
Chernozemsky, 1979; Waalkes et al., 2007; Yu et al., 2006a). Scientists at Oregon State
University demonstrated that DBC is a transplacental carcinogen in the mouse offspring
from a cross of strains B6129F1/J dams and 129S1/SvlmJ sires (Yu, et al., 2006a). Mice
treated with DBC had a high incidence of mortality due to aggressive T-cell
lymphoblastic lymphoma as early as three months of age. Furthermore, mice surviving to
ten months of age had a 100% incidence of lung adenomas (Yu, et al., 2006a). In
subsequent studies, this group determined the critical role of CYP1B1 in DBC-initiated
transplacental carcinogenesis in the development of the T-cell lymphoblastic lymphoma
(Castro et al., 2008a). A cross fostering study demonstrated that the two to three day in
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utero exposure to DBC resulted in much higher lymphoma-associated mortality than
exposure to the residual DBC in the breast milk over three weeks of nursing, thus
establishing that a brief exposure in utero is primarily responsible for the cancer response
(Castro et al., 2008b). All the previously mentioned transplacental mouse models utilized
a single dose of 15 mg/kg administered on gestation day (GD) 17. To more closely model
episodic exposure throughout pregnancy, researchers dosed pregnant dams with four
smaller amounts of DBC (3.75 mg/kg) on GD 5, 9, 13, and 17 (Shorey et al., 2012). This
multiple dosing regimen lessened the lung tumor response in offspring at 10 months of
age and eliminated mortality due to T-cell lymphoblastic lymphoma. These observations
suggest that the target tissue response for transplacental PAH carcinogenesis in this
mouse model is largely dependent upon the stage of fetal development upon exposure.
Many chemical carcinogens exist in the environment as inert procarcinogens that
require biological activation. Such is the case for PAHs, which are procarcinogens
requiring metabolic activation by phase I cytochrome (CYP) P450 enzymes to generate
their highly carcinogenic metabolites. CYP1A1 and CYP1B1 of the CYP1 family are the
main enzymes to carry out metabolic activation of PAHs, while the other CYP enzymes
in humans that play a lesser role in PAH metabolism, including CYP1A2, CYP2C9,
CYP3A4 and CYP3A5 (Shimada and Fujii-Kuriyama, 2004). Metabolic activation of
BaP is initiated by CYP1A1 oxidation to generate (+)- and (-)-BaP-7,8-oxides (Fig. 3).
Then, epoxide hydrolase hydrolyses these oxides to produce (-)- and (+)-BaP-7,8-diol,
which are further activated by CYP to highly reactive bay region epoxides, (+)-BaP-7,8diol-9,10-epoxide. The unstable epoxide intermediates may undergo conjugation with
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FIG. 3. Pathways for metabolic activation of benzo[a]pyrene.

glutathione (GSH) catalyzed by glutathione-s-transferases (GST) (Armsrong, 1997),
nonenzymatic isomerization to phenols, or hydration catalyzed by epoxide hydrolase to
form trans-dihydrodiols (Guenthner and Oesch, 1981). The GSH-conjugated metabolites
are primarily excreted in the bile or transported to the kidney where they are converted to
urinary excretable mercapturic acid conjugates (Hall and Grover, 1990). The phenol
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conjugates may undergo further conjugation reactions with glucuronic acid or sulfate
catalyzed by UDP-glucoronosyltransferase (UGT) and sulfotransferases (SULT),
respectively. Both the sulfate and glucuronide conjugates are water soluble and easily
excreted from the body (Burchell et al., 1997; Duffel, 1997). The highly reactive diolepoxide metabolites may undergo enzymatic conjugation with GSH or, alternatively, may
covalently bind to cellular nucleophiles such as DNA, thereby forming DNA adducts
(Hall and Grover, 1990). The stereo selectivity of PAH metabolism determines the
configuration of the formed DNA adducts in each individual case. Depending upon the
configuration of certain groups around the chiral center, there will theoretically be
multiple conformations for any given DNA adduct (Harvey, 1991). BaP predominantly
reacts with deoxyguanosine (dG) bases while DBC predominantly binds to
deoxyadenosine (dA) residues to form DNA adducts (Mahadevan et al., 2007). However,
not all DNA adduct formations have the same biological effect. The BaP-7, 8-diol-9, 10epoxide is a classical example which may form 16 different conformations in double
stranded DNA. The (+)-trans-anti-BaPDE-N2-dG renders a high tumorigenicity (Conney,
1982; Huberman et al., 1976; Newbold and Brookes, 1976; Phillips, 1983; Weinstein et
al., 1976).
Fjord region PAHs, such as DBC, are the most carcinogenic PAHs tested, thus far
(Bostrom, et al., 2002; Higginbotham et al., 1993). Their potency is due, in part, to
repulsive interactions between the two opposing hydrogen bonds present at the fjord
region (Fig. 4). This repulsion renders the molecule out of plane such that the dihyrodiolepoxides can bind more extensively to DNA as compared to PAHs with only a bay region
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FIG. 4. Pathways for metabolic activation of dibenzo[def,p]chrysene.
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(e.g., BaP) (Geacintov et al., 2002; Wu et al., 2002). These structural effects of the fjord
region conformation provide resistance to removal by DNA repair enzymes, leading to a
higher incidence of tumor initiation (Buterin et al., 2000; Chakravarti et al., 2000).
Expression of CYP1A1, CYP1A2 and CYP1B1 is induced by the presence of
PAHs (Iwanari et al., 2002). Exposure to PAH procarcinogens increases the expression
of the phase I enzyme that is responsible for their bioactivation. The induction of
CYP1A1 expression is regulated by the intracellular aryl hydrocarbon receptor (AhR) to
which PAHs chemically bind with high affinity. In the cytoplasm, AhR forms a complex
with the 90 kDA heat shock protein, the X-associated protein 2 and co-chaperone protein.
Following ligand binding, the AhR complex translocates into the nucleus, dissociates
from the protein complex and binds to a nuclear protein called the AhR nuclear
translocator (ARNT). Formation of the AhR-ARNT heterodimer converts the complex
into its high affinity DNA binding form, which subsequently binds to its specific DNA
recognition sites, the xenobiotic responsive elements (XREs), located upstream of the
CYP1A1 gene. The binding of XRE results in an increase in chromatin and nucleosome
disruption, an increase in promoter accessibility and an increase in the transcription of the
CYP1A1 gene (Denison et al., 2002; Whitlock, 1999).
Expression of phase I enzymes appears to play a role in the site of cancer
development as demonstrated by their tissue specific expression patterns (Choudhary et
al., 2003; Choudhary et al., 2005; McKinnon et al., 1991; Saarikoski et al., 1998).
CYP1A1 is primarily expressed in extrahepatic tissues such as the lung (Nelson et al.,
1996). The CYP1B1 gene is highly expressed in many human organs including brain,
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endometrium, placenta, fetal adrenal glands, lung, kidney, and lymphocytes (Hakkola et
al., 1997; Sutter et al., 1994), although its expression in the liver is rather low. CYP1B1
has been shown to activate BaP to its ultimate carcinogen metabolite at rates higher than
CYP1A2 but lower than CYP1A1 (Kim et al., 1998). On the other hand, CYP1A1 and
CYP1B1 appear to differ in their stereo-selective activation of DBC. CYP1B1 has been
shown to form higher portions of the highly carcinogenic metabolite of DBC, as
compared to CYP1A1 (Luch et al., 1998).
Epigenetics and Lung Cancer
The term epigenetics refers to specific patterns of chromatin structure and DNA
modifications that remain constant through the rounds of cell division, but that do not
involve changes to the DNA sequence. The epigenome is another layer of cellular
information that controls, registers or signals altered chromosome and gene activity
(Bird, 2007). Genes can become inactivated or permanently silenced by at least three
pathways: 1) a gene can become mutated and lose its functionality, 2) a gene can become
completely lost and thus not be available to perform its function and 3) a gene that has
not been lost or mutated can be switched off through changes to its epigenetic code.
Different combinations of pathways participate and cooperate with each other to cause
either a gain of function or loss of function in critical regulatory genes (Baylin and Jones,
2007). Genetic and epigenetic abnormalities can cause heritable disruptions to
homeostatic pathways by two different mechanisms. Either the activation of an oncogene
can occur resulting in a gain of function or tumor suppressor genes can be inactivated
resulting in a loss of function (Hanahan and Weinberg, 2000; Herman and Baylin, 2003;
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Jones and Baylin, 2002). These epigenetic changes can involve histone modifications,
chromatin remodeling and methylation of cytosine in CpG sites within the promoter
regions of genes.
Histone modifications and chromatin remodeling are two interrelated processes
that are regulated by post translational modifications of the nucleosome. The base unit of
packaged DNA is called a nucleosome, which consists of 146 base pairs (bp) of DNA
wrapped around an octamer of four core histone proteins (Luger et al., 1997). Histone
proteins are an essential part of DNA packaging and chromosome structure. The Nterminus amino acid tail of the histone protein protrudes away from the nucleosome
which provides multiple sites for post translational modifications, including acetylation,
methylation, ubiquitination and phosphorylation, that establish the histone code
(reviewed in Delage and Dashwood, 2008). These epigenetic modifications regulate gene
expression through the remodeling of the chromatin state. For example, methylation of
particular residues on histone tails is key modification for regulating chromatin
packaging and gene expression. In addition, acetylation of specific sites of the histone
protein aid in the regulation of chromatin folding and transcriptional activation.
Transcriptionally active regions of the genome reside in euchromatin, a decondensed
chromatin state, whereas inactive regions reside in heterochromatin defined as highly
compacted chromatin state. Due to the variety of epigenetic modifications, chromatin is a
highly dynamic structure, prone to remodeling and restructuring as it receives input from
upstream signaling pathways. The histone code works in concert with the DNA
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methylation code to ensure an efficient regulation of chromatin structure and genes
transcription (Delage and Dashwood, 2008).
CpG methylation can contribute to tumorigenesis via one of at least three
mechanisms. These include global hypomethylation of the genome, focal
hypermethylation of the proximal promoter region of tumor suppressor genes and
transversions, in which meCpG is converted to TpG (Baylin and Jones, 2007). Three
different types of DNA methyltransferases (DNMTs) are responsible for the methylation
of DNA. DNMT1 is responsible for the maintenance methylation or the upkeep of the
methylation code during cell replication. DNMT3a and 3b are responsible for the de novo
methylation, that is, the initial pattern of methylation established during early
development.
The misregulation of genes controlling cell proliferation, cell cycle, DNA repair,
inflammation, growth suppressor evasion, angiogenesis and cell metabolism can
contribute to the development of tumorigenesis (Hanahan and Weinberg, 2011). Lung
cancer involves an accumulation of genetic and epigenetic events in the cell (Dumitrescu,
2012). Alterations of the epigenome have been associated with many cancers, in which a
general pattern of DNA global hypomethylation and promoter hypermethylation have
been observed. Although mutations in tumor suppressor genes and oncogenes are
important for tumorigenesis, epigenetic modifications that also arise in response to DNA
damage have a crucial role in cellular selection, leading to a growth advantage for the
tumor cells at the expense of the host (Timp and Feinberg, 2013). Epigenetic alterations
are, in fact, more frequent than somatic mutations in lung cancer (Brzezianska et al.,
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2013). Epigenetic variation in progenitor cells together with genetic lesions drives tumor
progression. This early role for epigenetic alterations in cancer is in addition to epigenetic
alterations that can substitute for genetic variation later in tumor progression.
Epigenetically disrupted tumor suppressor genes in progenitor cells might be crucial
targets for cancer risk assessment (Feinberg et al., 2006). Promoter methylation of
specific tumor suppressor genes, along with the overall number of hypermethylated
genes, increased with neoplastic progression from hyperplasia to adenocarcinoma (Chung
et al., 2011; Licchesi et al., 2008).
There have been numerous studies examining the functions of gene inactivation
by promoter hypermethylation with respect to impacting tumorigenesis. Cyclindependent kinase inhibitor 2a (Cdkn2a, also known as p16INK4a) was the first tumor
suppressor gene found inactivated in lung cancer predominantly through aberrant gene
promoter hypermethylation (Merlo, et al., 1995). Cdkn2a inhibits the cyclin-dependent
kinases 4 and 6, which bind cyclin D1 and phosphorylate the retinoblastoma tumor
suppressor gene (Lukas et al., 1995; Weinberg, 1995). Since the identification of Cdkn2a
inactivation by promoter hypermethylation, epigenetic silencing has been associated with
numerous other genes in lung cancer (Belinsky, 2004; Tsou et al., 2002). Methylation of
the death-associated protein kinase (Dapk1) and retinoic acid receptor β (Rarb) genes
were detected in approximately half of alveolar hyperplasia induced mouse lungs
chronically exposed to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) (Pulling,
et al., 2004; Vuillemenot, et al., 2004). Loss of function for these two genes could
significantly affect cellular apoptosis and normal cell differentiation control. O6-
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methylguanine-DNA methyltransferase (Mgmt) is a DNA repair enzyme that protects
cells from the carcinogenic effects of alkylating agents by removing alkyl adducts from
the O6 position of guanine. The predominant mechanism for Mgmt gene inactivation is
hypermethylation within its promoter region that leads to transcriptional silencing in 27–
47% of lung adenocarcinomas (Esteller, et al., 1999; Furonaka, et al., 2005). The
important functions of these genes and others inactivated through promoter
hypermethylation supports a role for their involvement in the initiation and progression of
lung carcinogenesis.
Several in vitro studies have shown that treatment of human cells with BaP or the
carcinogenic metabolite benzo[a]pyrene-diolepoxide (BPDE) results in altered histone
modification (Sadikovic et al., 2008), gene-specific DNA hypo-and hypermethylation
(Damiani et al., 2008; Sadikovic and Rodenhiser, 2006) and altered expression of key
genes involved in cancer cell transformation (Damiani, et al., 2008). Damiani, et al.
(2008) functionally linked BPDE-induced changes in DNA methylation in transformed
human bronchial epithelial cells from smokers with lung cancer to increased expression
of DNMT1 (but not DNMTs 3a or 3b) and de novo methylation of a number of tumor
suppressor genes, including E-cadherin, H-cadherin, protocadherin-10, Rassf2a and
Pax5α among others. These early studies provide initial evidence that PAHs, specifically
BaP, are capable of epigenome modification. However, it is not known whether in vivo
exposure to PAHs disrupts patterns of gene promoter methylation. Moreover, it is also
unknown whether transplacental exposure to PAHs alters the fetal/neonatal epigenome,
specifically.
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Table 1 shows the methylation prevalence of four specific tumor suppressor genes
known to be hypermethylated in human lung cancer and some mouse chemical cancer
models. These four genes have diverse functions in carcinogenesis and were the focus of
a major portion of the present study. Methylation prevalence is the ratio of the number of
occurrences for detected methylation in the population studied.
Project Objectives and Hypothesis
The objective of this project was to determine the impact of transplacental exposure
of PAHs on the neonatal and adult offspring epigenome in the mouse lung. We
hypothesized that transplacental exposure to PAHs alters DNA methylation in the
promoter region of key tumor suppressor genes leading to increased risk of lung cancer in
the adult. The specific objectives were as follows:
1. Determine the impact of transplacental exposure to DBC and BaP on methylation of
the promoter regions of the Cdkn2a, Rarb, Dapk1 and Mgmt genes in neonate
mouse lung. Determine the impact of transplacental exposure to DBC and BaP on
genome-wide methylation of the lung tumors in the adult offspring mice.
2. Assess the timing of tumor suppressor gene silencing resulting from gestational

PAH exposure by measuring gene promoter methylation in adult mice (aged 15 to
45 weeks) as preneoplastic lesions develop into lung adenocarcinomas in the adults.

Rarb

Dapk1

Retinoic acid receptor β

Death-associated protein
kinase

13-67%, AdC1
26-29%, NSCLC2

Human Tumorsa

Apoptosis

24-48%, AdC5
17-44%, NSCLC6

Cell proliferation 30%, AdC3
Apoptosis
38-45%, NSCLC44

Cell cycle

Function

90%, Arsenic9
83%, Aflatoxin10
0%, NNK11
70% methylene chloride12
85%, NNK13
90%, Cigarette smoke14
56%, methylene chloride15
60%, vinly carbamate16
52%, NNK17
43%, Cigarette smoke18
60%, methylene chloride19
50%, vinyl carbamate20

Mouse Tumorsb

O6-methylguanine-DNA
Mgmt
DNA repair
27-47%, AdC7
methyltransferase
29-38%, NSCLC8
Note: NSCLC, non-small cell lung carcinoma; AdC, adenocarcinoma; NNK, nicotine-derived nitrosamine ketone.
a
Reported range of methylation prevalence in human lung tumors.
b
Methylation prevalence in mouse lung tumors from carcinogen exposure studies.
1
(Kim et al., 2001b; Zochbauer-Muller et al., 2001); 2 (Fischer et al., 2007; Guo et al., 2015; Merlo et al., 1995); 3
(Toyooka et al., 2003a); 4 (Fischer, et al., 2007; Guo, et al., 2015; Virmani et al., 2000); 5 (Kim et al., 2001a; Tang et al.,
2000; Toyooka et al., 2003b); 6 (Fischer, et al., 2007; Guo, et al., 2015; Tang, et al., 2000); 7 (Furonaka et al., 2005; Pulling et
al., 2003; Zochbauer-Muller, et al., 2001); 8 (Esteller et al., 1999; Fang et al., 2014; Guo, et al., 2015); 9 (Cui et al., 2006); 10
(Tam et al., 2003); 11 (Belinsky, 2005); 12 (Patel et al., 2000); 13 (Vuillemenot et al., 2004); 14 (Vuillemenot, et al., 2004); 15
(Vuillemenot, et al., 2004); 16 (Vuillemenot, et al., 2004); 17 (Pulling et al., 2004); 18 (Pulling, et al., 2004); 19 (Pulling, et al.,
2004); 20 (Pulling, et al., 2004)
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Gene
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Select Genes Altered by Hypermethylation in Lung Cancer
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MATERIALS AND METHODS
Chemicals
DBC and BaP were purchased from Sigma-Aldrich (St. Louis, MO; CAS No.
191-30-0, CAS No. 50-32-8). Buffered 10% neutral formalin was purchased from VWR
(Houston, TX). Optimal Cutting Temperature (OCT) Compound was obtained from
Sakura Finetek (Torrence, CA). Arcturus® HistoGene® staining solution was purchased
from Applied Biosystems (Foster City, CA). All other chemicals used were of reagent
grade and purchased from general laboratory suppliers.
Animals
The Utah State University Institutional Animal Care and Use Committee
approved all procedures for the handling and treatment of mice used in this study
(Protocol #1442). Animals were housed in the USTAR BioInnovations Center’s
Vivarium at Utah State University. All mice were maintained on a 12:12 hour dark:light
cycle, and water was provided ad libitum. Eight week old B6129SF1/J females and
129S1/SvImJ males were obtained from the Jackson Laboratory (Bar Harbor, ME) and
bred to obtain a backcross strain that is sensitive to DBC and BaP as transplacental
carcinogens (Castro, et al., 2008a; Yu, et al., 2006a). Moreover, B6129SF1/J mice
possess an AhR-responsive allele, meaning that these mice are prone to carcinogenesis
induced by PAHs via induction of Cyp1b1 and/or Cyp1a1 (Yu, et al., 2006a).
Furthermore, the mouse Cyp1b1 has the highest activity toward conversion of DBC to the
carcinogenic fjord region diol-epoxide (Castro et al., 2008c; Luch, et al., 1998). Dams
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were fed AIN93G (Harlan-Teklad, Madison, WI) during pregnancy and lactation.
Weaned offspring were fed AIN93G until three months of age, and were then fed
AIN93M diet (Harlan-Teklad, Madison, WI) ad libitum until euthanasia.
Experiment Design
B6129SF1/J dams and 129S1/SvImJ sires were bred and day one of gestation was
determined by the detection of the vaginal plug. On gestation days 5, 9, 13 and 17,
pregnant mice were dosed by body weight with vehicle (5 ml/kg/day corn oil), 3.75
mg/kg/day DBC (total dose 15 mg/kg) or 12.5 mg/kg/day BaP (total dose 50 mg/kg). Any
mice exhibiting signs of morbidity, pain or distress during the study were humanely
euthanized with an overdose of CO2 and necropsied.
For the sham treatment group (group 1), 11 females were bred to 5 males to
generate 93 pups. For the DBC group (group 2), 13 dams were bred to 7 males to
generate 89 pups. Because BaP is a less potent carcinogen compared to DBC, we
generated more animals for group 3 using 15 dams and 8 males to produce 131 offspring.
Four litters from each group were used to obtain lung tissue from neonate offspring at
day one of age. From these neonates, lung, liver, thymus and heart were collected and
immediately frozen in liquid nitrogen and stored at -80°C. The tissues from all pups
within each litter were combined to provide sufficient tissue for analysis, resulting in n =
4 for each experimental group.
At ages 15, 25, 35 and 45 weeks, six mice from group 1 and 2 and ten mice from
group 3 were randomly selected to be euthanized to obtain tissues samples throughout the
progression of lung tumor development, including normal tissue, preneoplastic lesions

25

FIG. 5. Representative microscopy images of mouse lung tissues collected for laser
capture microdissection. (A) normal lung tissue, (B) atypical adenomatous
hyperplasia, and (C) adenocarcinoma.

(atypical adenomatous hyperplasia [AAH]) and lung adenocarcinomas. Example images
depicting these tissue types in mouse lung are shown in Fig. 5. Lung tissues were
collected and embedded in OCT for later processing and use in laser capture microdissection (LCM). At 45 weeks, all remaining offspring from all experimental groups
were humanely euthanized by CO2 asphyxiation and necropsied. Lung tumors present on
the lungs of these 45 week-old mice were identified, counted and the diameter was
measured by digital caliper. Half the lung was placed in the 10% neutral buffered
formalin, while the other half was frozen in liquid nitrogen and stored at -80°C. At each
necropsy, body weights and spleen, kidney, liver, and heart weights were recorded; these
organs were stored in 10% buffered neutral formalin.
Lung Tissue Collection and Processing
Lung tissues designated for analysis by LCM were processed in two halves, each
of which was placed into a 12×12×20 mm embedding mold, covered with OCT
compound and then submerged in chilled isopentane until solidification of OCT,
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according to the supplier’s protocol. Frozen tissue blocks were stored at -80°C until
further processing.
Sectioning of the tissue blocks was completed using the Leica CM1950 cryostat
(Leica Biosystems, Buffalo Grove, IL). Tissue sections were cut with 8 µm thickness and
placed onto Arcturus® polyethylene naphthalate (PEN) membrane slides (Applied
Biosystems, Foster City, CA). The slides were immediately placed into a microslide box
on dry ice. Next, slides were immersed in 75% ethanol (v/v) for 30 sec followed by
distilled water for 30 sec and then removed. Next, 100 µl of Arcturus® HistoGene®
staining solution was applied to each slide for 20 sec. Then, slides were sequentially
immersed for 30 sec each in distilled water, 75% (v/v) ethanol, 95% (v/v) ethanol and
100% ethanol and then finally 5 min in xylene. The slides were dried in a ventilated hood
for an additional five minutes and then stored at -80°C until LCM.
Slide sections were examined by a board certified Veterinary Pathologist at the
Utah Veterinary Diagnostics Laboratory to localize tissue types to be collected by LCM.
For this analysis, only tissues from mice in group 1 (sham) and group 2 (DBC-initiated)
were used. Tissue types collected for LCM included normal adjacent lung, AAH and lung
adenocarcinomas for mice aged 25 to 45 weeks initiated with DBC in utero (group 2).
Only normal lung tissue was collected for mice in group 1 at all ages and for mice in
group 2 at age 15 weeks as there was no evidence of AAH in DBC-initiated offspring at
this age. Tissues were collected from four of the six mice euthanized at each time point,
as not all tissue types were evident in every mouse (i.e., AAH was evident in only four of
the six mice collected at 25 weeks).
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LCM collection was performed on Arcturus® Veritas™ laser capture micro
dissection instrument at the University of Utah Cell Imaging core facility. LCM was
performed using an infrared (IR) laser, which captured the cells of interest directly onto
Arcturus® CapSure® Macro LCM caps (Applied Biosystems, Foster City, CA). Caps with
tissues were then snapped onto 0.5 ml microcentrifuge tubes, and then DNA from the
captured tissues was extracted using the Arcturus® PicoPure® DNA Extraction Kit
(Applied Biosystems, Foster City, CA) according to the supplied protocol with no
deviation.
Frozen lung tissues from neonate offspring were pooled by litter (n = 4 litters per
group), and DNA and total RNA were isolated from these tissues using TRI Reagent®
(Sigma-Aldrich, St. Louis, MO) according to the supplier’s protocol.
Roche 454 Sequencing
DNA collected from LCM-captured lung tissues from group one and two mice
and from neonate lungs was utilized for bisulfite deep sequencing. All DNA samples
were bisulfite-converted using the EZ DNA Methylation Kit™ (Zymo Research, Irvine,
CA). Then, the bisulfite-converted DNA was subject to a genomic pre-amplification step
using Fluidigm’s Specific Target Amplification (Preamplification) protocol (Fluidigm,
South San Francisco, CA). Table 2 shows the primer sequences utilized for
preamplification and library preparation, and Fig. 6 shows the location of primer sets
with respect to predicted CpG islands for each target gene. Genomic sequence
information was obtained from the Ensembl Genome Browser (Flicek et al., 2012), and
primer sequences were designed using MethPrimer software (Li and Dahiya, 2002). The
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TABLE 2
Primers Used for Bisulfite Sequencing
Gene

Primer (5’ to 3’)

Positiona CpG sites

Cdkn2a
For
[CS1]-GATGGATTTGGAGTAAGGGAAA
-366
41
Rev
[CS2]-CCCAAAAACRCCCAAAAA
-86
Dapk1
For
[CS1]-GTGTGGGGGTTTTTTAGTTTAGATT
340
22
Rev
[CS2]-CTTCCTAATACCTACCCAATTCCTC
635
Mgmt
For
[CS1]-GTTTTAGGTTTGGAAGAAGAGGTTT
-280
20
Rev
[CS2]-CACAAATTTTAAATACCTAAACACCAA
15
Rarb
For
[CS1]-GGTTTGGTTAGGAATAGGAGAGTAGA
-351
17
Rev
[CS2]-AACAACCCTACAAAAACCTTCAAC
-165
Note: For, forward primer; Rev, reverse primer; CS1, common sequence tag 1 (5’acactgacgacatggttctaca-3’); CS2, common sequence tag 2 (5’-tacggtagcagagacttggtct-3’).
a
Position number specifies the bp location of the genomic primer’s 5’ end in relation to the
first bp of the first exon of the gene.

FIG. 6. Location of primer sequences with respect to predicted CpG islands for
selected genes. Red arrow pairs indicate regions targeted for generating amplicons for
ultra-deep bisulfite sequencing. The scale indicates position with respect to the
transcript start site at exon 1 (first black bar). CpG islands (light blue) were predicted
using EMBOSS Cpgplot (Li et al., 2015).
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genome target specific primers were designed to contain a 22 bp Fluidigm forward or
reverse common sequence tag (CS1 or CS2) at the 5’ end.
The Fluidigm 48.48 Access Array system was used for library preparation of the
samples and our four target genes following the manufacturers supplied protocols.
Briefly, bisulfite-modified preamplified DNA was combined with master mix from the
FastStart High Fidelity PCR System, dNTPack (Roche, Bradford, CT) following
manufacturer’s protocol and then loaded into the primed 48.48 access array plate. Each
plate was run on the BioMark system (Fluidigm, South San Francisco, CA), which
utilizes Fluidigm’s integrated fluidic circuits for automating the PCR reactions in
nanoliter volumes. Three 48.48 access array plates were utilized to amplify all samples,
and each gene was duplicated eight times across both plates with one exception. Mgmt
was duplicated 16 times on each plate in order to more closely balance the ultimate yield
of sequence reads from each amplicon, as amplification of Mgmt was roughly half as
efficient as the other genes. Products from the Access Array were subjected to
electrophoresis on a 2% agarose gel for visual conformation of adequate amplification
and appropriate amplicon size. Gel bands corresponding to each amplicon were excised,
and DNA was extracted using Qiagen’s QIAquick® Gel Extraction Kit (Qiagen,
Valencia, CA). A secondary amplification, using a standard thermocycler, was performed
utilizing primers that contained the 25 bp Roche 454 A and B adaptor sequences (adapter
A, CGTATCGCCTCCCTCGCGCCATCAG on the forward primer and adapter B,
CTATGCGCCTTGCCAGCCCGCTCAG on the reverse primer), the 10 bp multiplex
identifier (MID) and the CS1 or CS2 tags, respectively. This second round of PCR used
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1µl of the PCR product from the first round and 2 µM primer in master mix from the
FastStart High Fidelity PCR System, dNTPack (Roche, Bradford, CT) and the following
cycling parameters: 95°C for 10 min for 1 cycle, 95°C for 15 sec, annealing temperature
of 60°C for 30 sec, and 72°C for 1 min for 15 cycles and the final stage of 72°C for 3 min
for 1 cycle. At the conclusion of the second round of PCR, the amplicons contain all the
necessary elements for 454 sequencing.
DNA samples were then subjected to electrophoresis on a 2% agarose gel for
visual conformation of adequate amplification and appropriate amplicon size. The DNA
bands were excised and DNA was extracted using Qiagen’s QIAquick® Gel Extraction
Kit. Finally, the fully processed DNA was sent to the Center for Integrated BioSystems at
Utah State University to be sequenced on the Roche 454 Sequencer (Roche, Bradford,
CT). Briefly, amplicon libraries were subjected to emulsion PCR to produce DNA-coated
beads, loaded onto a 70×75 PicoTiterPlate, and sequenced using the FLX Titanium DNA
sequencing Kit according to the manufacturer’s protocol.
NimbleGen DNA Methylation Array
Genome-wide DNA methylation analysis of offspring lung tissues was performed
using the NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq
Promoter Array (Roche NimbleGen Inc., Basel, Switzerland). Tissue types analyzed
included normal lung tissue from sham-initiated offspring and normal adjacent lung
tissues and lung tumors from 45 week-old offspring initiated with DBC or BaP in utero.
High-quality genomic DNA was extracted from lung tissue using the DNeasy Blood &
Tissue Kit (Qiagen, Valencia, CA). One microgram of genomic DNA was restriction-
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digested with Mse I restriction enzyme (New England BioLabs, Ipswich, MA) to generate
200 to 1000 bp fragments. Samples were subjected to heat denaturation for 20 min at
65°C in order to stop the reaction. DNA samples were then purified using QIAquick PCR
Purification Kit (Qiagen, Valencia, CA), and DNA concentration was determined using a
NanoDrop spectrophotometer (Thermo Fisher Scientific). Verification of fragment size,
using 200 ng of sample was performed by gel electrophoresis (2% agarose gel). An
aliquot of 10 to 15 ng was reserved after quantification for use as control (input DNA).
The remainder was immunoprecipitated using the Methylated-DNA IP Kit (Zymo
Research, Irvine, CA; Cat. No. D5101). Because the quantity of MeDIP DNA obtained
was insufficient for processing the genome-wide arrays, a whole-genome amplification
step was required. Whole-genome amplification was performed utilizing a series of two
kits with a starting amount of 10 ng for both input and MeDIP DNA as per
manufacturer's instructions. The first kit used was GenomePlex® Complete Whole
Genome Amplification (WGA) Kit (Sigma-Aldrich Company, St. Louis, MO), or WGA2
kit. The second was GenomePlex® WGA Reamplification Kit (Sigma-Aldrich Company,
St. Louis, MO) or WGA3 kit. Following processing of samples through this two-kit
procedure, the WGA-amplified DNA was then purified using QIAquick PCR Purification
Kit (Qiagen, Valencia, CA), and 5 µg of DNA per sample were provided to NimbleGen
(Roche NimbleGen Inc, Basel, Switzerland) for array hybridization and preliminary data
processing.

32
Data Analysis
Statistical analysis of lung tumor multiplicity was performed using one-way
ANOVA with Bonferroni’s test for multiple comparisons (GraphPad Prism vers. 6,
LaJolla, CA). Lung tumor incidence in 45-week old offspring exposed in utero to BaP
was analyzed using Fisher’s exact test (GraphPad Prism).
Sequencing data generated by Roche 454 were processed using Amplicon Variant
Analyzer (Roche, Bradford, CT). Sequences were separated by sample according to their
barcode sequences, and barcodes were trimmed off. The resulting sequences were then
aligned to reference sequences for each amplicon and the primer sequences were
trimmed. BioEdit Sequence Alignment Editor was then used to prepare and edit the
individual alignment files for each sample/amplicon (Hall, 1999).
The processed data were subjected to analysis of CpG methylation frequency
using the Bisulfite Sequencing DNA Methylation Analysis (BISMA) program (Rohde et
al., 2010). First, data files (limited to 400 sequence reads per file) uploaded to BISMA
were automatically subjected to a multiple sequence alignment and quality control
analysis on the following parameters: defined quality and specificity criteria of sequence
identity, percentage of insertions/deletions, conversion rate and percentage of unresolved
annotations. Sequences that did not pass these quality criteria were automatically
removed from subsequent analysis. BISMA analysis generated output for each sequence
analyzed, including the calculated average methylation at each CpG position and the
average methylation for the entire sequence. Also, the program generated an aligned
sequence map depicting methylation status for each CpG site for each included sequence.
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Data received from NimbleGen’s genome-wide DNA methylation analysis
consisted of processed data files as well as the raw data files for all samples submitted.
Raw data files contained signal intensity data from the scanned images of each array
obtained using NimbleScan. Peak data files (processed data files) were generated from
the raw signal intensity data by Nimblegen. Briefly, for each array feature, a scaled log2
ratio was calculated as the ratio of the input signals for the experimental and control
samples co-hybridized to the array. The log2 ratio was computed and scaled to center the
ratio data around zero. Scaling was performed by subtracting the bi-weight mean for the
log2 ratio values for all features on the array from each log2 ratio value. From the scaled
log2 ratio data, a fixed-length window (750 bp) was placed around each consecutive
probe, and the one-sided Kolmogorov-Smirnov (KS) test was applied to determine
whether the probes are drawn from a significantly more positive distribution of intensity
log-ratios than those in the rest of the array. The resulting score for each probe is the
−log10 p-value from the windowed KS test around that probe. Using NimbleScan, peak
data files were generated from the p-value data files. NimbleScan detects peaks by
searching for at least two probes above a −log10 p-value minimum cutoff of 2. Peaks
within 500 bp of each other were merged. Finally, the “peak score” was calculated as the
average −log10 p-values from probes within that peak. Two sets of processed data files
with these calculated peak scores were generated by Nimblegen. One set contained data
for all peak scores near a given transcript, while the second set included data for only the
peak score nearest the transcription start site of a given gene.
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Gene lists for functional ontology analysis were generated by selecting features
with peak score > 2 (indicative of methylated DNA) in all three samples from the
treatment group of interest and by excluding all features that were not methylated (peak
score <2) in at least 2 of the 3 samples from the comparison treatment group(s). Using
these criteria, for example, genes listed as methylated in sham samples were consistently
methylated in only the sham tissues and mostly not methylated in other tissues. Gene
ontology analysis was performed using the AgriGO singular enrichment analysis (SEA)
tool (Du et al., 2010) against the mouse gene ontology database (Mouse Genome
Informatics) with the following parameters: Fisher test with FDR under dependency
correction and significance level of P<0.05 and the minimum number of mapping entries
set at five genes. The gene ontology type performed was a generic GO slim (Gene
Ontology Consortium).
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RESULTS
Lung Tumorigenesis in 45 Week-Old Offspring
Lung tumor incidence was 29.5% in 45 week-old offspring initiated in utero with
BaP, much lower than the 100% incidence rate observed for the more potent carcinogen
DBC (Fig. 7A). The spontaneous lung tumor rate in sham-initiated offspring mice at 45
weeks of age was 8.9%. A similar pattern was observed for lung tumor multiplicity,
calculated as the number of lung tumors per tumor-bearing animal (Fig. 7). Shaminitiated mice that developed lung cancer spontaneously did so with a very low
multiplicity (one tumor per animal), and multiplicity in BaP-initiated offspring was
similarly low with only one to two tumors per animal. Alternatively, DBC-initiated

FIG. 7. Lung tumorigenesis in offspring exposed to PAHs in utero. (A) Values for
tumor incidence are indicated by the height of the bar for each group, and tumor
multiplicity is indicated by bar shading. ***, P < 0.001 for tumor multiplicity
compared to Sham and BaP treatment groups as determined by one-way ANOVA with
Bonferroni’s post hoc test for multiple comparisons. (B) Values shown are the percent
of male and female offspring initiated in utero with BaP with lung tumors at 45 weeks
of age. **, P = 0.0018 as determined by Fisher’s exact test.
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offspring had a significantly higher average tumor multiplicity of six tumors per tumorbearing animal (P < 0.0001). Interestingly, lung tumor incidence in 45 week-old
offspring exposed in utero to BaP was significantly lower in females (12%) compared to
their male counterparts (50%) (P = 0.0018) (Fig. 7B). Although statistical analysis
suggested that lung tumor incidence was different between the sexes in mice initiated
with BaP, this result should be interpreted with some caution given the relatively small
number of mice that developed tumors within this treatment group. There was no
apparent difference observed in lung tumor incidence in DBC-initiated mice, as all
animals exposed to this carcinogen developed lung cancer, as has been repeatedly
observed in this model (Castro, et al., 2008b; Risch, et al., 1993; Yu, et al., 2006a).
Amplicon Bisulfite Sequencing Analysis
DNA promoter methylation patterns were examined using bisulfite sequencing of
CpG sites at single base pair resolution across four genes from DNA collected via LCM.
The average percent methylation values corresponding to the CpG site sequenced are
provided in Tables 3-6, with the data organized according to the sample type, animal age
and the amplicon sequenced. Unsupervised bi-directional hierarchical clustering was
performed using average methylation data for each comparison group to identify
distinctions in methylation profiles according to age (neonate, 15, 25, 35 or 45 weeks),
type of carcinogen exposure (Sham, DBC or BaP) or tissue type (normal, AAH or
tumor). Clustering was also performed using methylation data for each individual mouse
to assess variation in methylation profiles within and across age, carcinogen exposure and
tissue-type groupings.
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TABLE 3
Average Methylation per CpG Site for the Cdkn2a Promoter Region Sequenced by Roche 454 a
CpG Site Number b

Age

Tissue
type

Number
reads c

Sham

Neonate

Normal

11

0.0 0.0 0.0 0.0 0.0 4.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 16.7 22.9 22.9 12.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

Sham

15wk

Normal

793

0.2 0.0 2.2 0.3 0.2 0.1 0.6 0.2 0.9 0.6 0.7 0.6 0.3 0.5 1.5 0.2 0.1 0.2 0.6 0.2 0.3 0.1 0.2 0.2 0.2 1.4 31.4 43.3 42.1 22.2 0.2 0.1 0.0 0.1 1.0 0.1 0.0 0.2 1.3 0.4 0.3

Sham

25wk

Normal

1042

0.6 0.4 3.6 1.8 0.9 1.2 0.3 6.9 0.5 1.0 0.3 0.4 0.3 0.2 0.7 0.4 0.3 0.7 0.4 0.9 0.0 0.2 0.2 0.4 1.3 0.7 15.6 24.0 14.2 11.8 0.2 0.2 0.4 0.4 0.2 0.1 0.5 0.3 0.5 0.2 0.0

Sham

35wk

Normal

915

0.2 0.2 0.2 0.8 0.6 1.0 0.1 0.6 0.5 0.3 1.0 0.0 0.2 0.7 1.7 0.6 0.2 0.8 0.5 0.5 1.2 0.2 0.2 0.3 0.7 0.8 18.4 26.6 23.2 11.4 0.5 0.8 1.1 0.5 0.2 0.2 0.7 0.1 0.3 1.3 0.2

Sham

45wk

Normal

654

0.0 0.4 0.6 1.3 0.0 0.5 0.2 0.5 0.3 0.3 0.4 0.4 0.3 0.2 0.1 0.1 0.7 0.0 0.1 3.7 0.6 0.2 0.5 0.0 0.1 0.2 55.1 60.5 61.2 30.5 1.2 0.2 0.5 0.4 0.2 0.3 0.0 0.4 0.1 0.2 0.0

DBC

Neonate

Normal

9

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 28.6 28.6 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

BaP

Neonate

Normal

21

0.0 0.0 0.0 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 20.7 40.7 40.7 12.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

DBC

15wk

Normal

149

0.5 0.0 0.0 0.5 0.5 0.3 0.3 0.0 0.0 0.0 0.0 0.0 0.0 2.8 0.5 0.0 0.3 0.3 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 15.9 21.6 21.6 7.1 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.3 3.5 0.3 0.3

DBC

25wk

Normal

409

0.9 1.1 0.3 0.9 0.2 0.9 0.5 0.5 0.6 0.5 0.2 0.5 0.3 0.6 0.8 0.4 0.0 0.0 1.0 0.9 0.8 0.8 0.6 1.2 1.3 0.4 12.3 18.0 20.3 5.1 0.9 0.2 1.2 1.0 0.2 0.2 0.2 0.0 0.5 1.0 0.3

DBC

25wk

AAH

324

0.1 0.8 0.0 0.0 0.3 0.4 0.0 2.0 1.1 0.0 0.6 0.0 0.0 1.4 0.8 0.0 0.0 0.1 3.6 0.1 1.5 0.0 1.1 0.1 0.5 0.0 10.6 9.9 11.4 6.6 0.0 0.0 0.9 0.3 0.0 0.0 0.1 0.0 0.1 0.1 0.0

DBC

25wk

Tumor

168

0.8 0.0 1.2 1.1 0.0 0.0 0.0 1.3 0.0 0.0 2.4 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.4 0.0 0.0 0.4 0.0 11.2 29.9 35.8 4.8 0.4 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.4 0.0

DBC

35wk

Normal

459

0.0 0.2 0.0 0.2 0.3 1.1 0.0 0.6 0.2 0.6 0.9 0.3 0.0 0.5 2.4 0.0 0.3 0.8 0.2 0.2 0.3 0.5 2.0 3.0 1.8 0.6 11.4 22.6 23.5 13.3 0.8 0.2 0.2 0.2 0.3 0.2 0.2 0.5 0.3 0.6 0.2

DBC

35wk

AAH

654

0.1 0.0 0.7 0.4 0.0 1.0 0.2 0.2 0.4 0.3 0.2 0.2 0.3 0.4 0.4 0.2 0.4 0.3 0.6 0.5 0.3 0.2 0.4 0.0 0.4 0.3 31.9 17.4 14.5 10.1 0.7 0.3 0.1 0.6 0.3 0.0 0.5 0.6 0.0 0.6 0.7

DBC

35wk

Tumor

830

0.6 0.2 0.0 0.8 0.3 0.9 0.4 0.7 0.7 0.3 0.0 0.3 0.2 0.3 0.5 0.1 2.5 0.1 0.3 0.8 0.3 0.2 0.3 0.0 0.2 1.0 22.1 40.2 37.6 20.5 1.0 0.6 1.4 0.3 0.2 0.0 1.8 0.1 0.5 0.6 0.4

DBC

45wk

Normal

1303

0.2 0.3 1.0 0.9 0.2 1.1 0.7 0.4 0.4 0.1 0.3 0.3 0.4 0.2 0.5 0.4 0.9 0.4 0.3 0.7 0.1 0.6 0.1 0.5 0.1 2.2 15.7 28.7 27.8 9.2 0.6 0.7 0.4 0.6 0.3 0.2 0.3 0.8 0.7 0.3 0.4

DBC

45wk

AAH

392

0.7 0.3 0.6 0.3 0.5 0.0 0.5 0.6 0.3 0.3 0.3 0.6 2.4 0.0 9.7 0.3 0.3 0.3 1.0 0.6 0.0 0.0 0.3 0.5 0.0 0.0 22.7 37.4 32.5 18.0 0.6 1.6 0.3 0.6 0.0 0.3 1.5 1.2 0.3 0.0 8.0

DBC

45wk

Tumor

852

0.2 0.1 0.2 0.2 0.5 0.1 0.3 4.0 0.7 0.3 0.3 0.2 0.1 0.2 0.9 0.3 0.8 0.2 0.0 0.2 0.0 8.8 0.1 0.2 1.4 0.0 17.4 30.1 29.1 16.1 1.0 0.1 0.2 0.0 0.4 0.0 0.7 1.2 0.5 0.2 0.6

Carcinogen

4

7

14 27 36 43 54 59 66 70 73 82

88

92 98 106 125 129 134 138 140 145 147 150 163 165 175 179 184 188 195 200 209 211 221 229 235 245 247 249 251

Color key
0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0
a

Each heat map cell indicates the percentage of CpG sites positive for methylation. Blue corresponds to low methylation and red to high methylation according to color key shown below the table.
CpG site number specifies the specific base pair location of the CpG site in relation to the first base pair of the first exon.
c
Number shown is the total number of reads associated with each amplicon for each sample.
b
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TABLE 4
Average Methylation per CpG Site for the Dapk1 Promoter Region Sequenced by Roche 454 a
CpG Site Number b
Carcinogen

Age

Tissue
type

Number
reads c

11

13

26

28

38

44

66

84

120

141

149

154

157

171

176

178

184

209

246

252

261

267

Sham

Neonate

Normal

Sham

15w

Normal

545

0.8

1.9

0.0

0.8

0.1

0.1

0.4

1.7

0.3

0.5

0.2

0.1

0.2

0.5

1.5

0.4

0.6

0.3

0.0

0.5

0.1

0.5

Sham

25w

Normal

1023

0.1

0.5

0.4

0.4

0.3

1.2

1.2

0.8

1.3

0.1

1.2

0.6

1.2

0.7

0.7

0.3

1.1

0.8

0.2

0.0

0.1

0.6

Sham

35w

Normal

246

1.5

1.4

0.0

0.5

0.6

0.7

0.0

0.0

0.9

0.8

0.0

2.0

3.3

0.9

1.3

0.9

1.1

0.0

0.0

0.0

0.7

0.5

Sham

45w

Normal

133

0.6

2.2

2.6

0.0

0.0

0.6

0.6

0.0

3.3

0.5

2.6

1.2

1.3

0.0

1.4

0.0

0.0

0.7

0.0

0.0

0.7

0.0

DBC

Neonate

Normal

d

BaP

Neonate

Normal

d

DBC

15w

Normal

55

0.0

2.1

0.0

0.0

0.0

0.0

1.4

0.0

0.0

0.7

0.0

0.0

0.0

0.7

0.0

0.0

0.0

0.0

0.0

0.7

0.0

0.0

DBC

25w

Normal

94

5.3

3.6

0.0

0.0

0.0

0.0

0.0

0.9

1.1

0.0

0.0

0.0

3.0

1.1

0.0

0.0

0.0

0.0

0.0

1.0

1.1

0.0

DBC

25w

AAH

41

4.2

7.0

0.0

0.0

0.0

0.0

0.0

4.2

2.8

4.2

0.0

0.0

0.0

0.0

0.0

0.0

10.7

4.2

4.2

4.2

0.0

4.2

DBC

25w

Tumor

33

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

4.8

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

DBC

35w

Normal

132

9.4

8.9

0.4

0.0

0.8

0.0

0.0

0.0

0.0

0.0

0.0

0.0

1.6

0.0

0.0

1.6

1.1

0.0

0.0

1.1

0.4

0.0

DBC

35w

AAH

72

4.4

4.9

0.0

0.0

0.0

0.0

0.0

2.6

8.4

2.8

0.0

1.4

1.7

2.6

2.9

9.3

0.0

3.0

0.0

0.0

0.9

0.0

DBC

35w

Tumor

178

1.5

1.3

0.0

0.0

0.7

0.0

0.0

0.0

1.6

0.4

2.2

1.7

0.4

1.2

0.0

0.0

0.7

2.8

0.0

0.0

1.3

2.0

DBC

45w

Normal

699

0.2

0.3

0.6

0.6

0.5

1.2

0.0

2.2

1.7

0.6

0.2

0.4

1.2

0.6

0.8

0.2

0.7

2.0

0.2

0.2

0.5

1.1

DBC

45w

AAH

229

4.9

4.9

4.6

5.0

0.0

4.6

4.5

0.0

7.4

4.3

4.6

4.0

4.3

4.6

4.6

5.2

4.9

4.9

1.0

1.0

1.4

0.3

DBC

45w

Tumor

269

0.9

2.5

0.0

0.2

0.1

0.0

0.0

0.3

0.0

0.3

0.3

0.0

0.0

0.0

0.0

0.0

1.6

0.1

0.0

0.0

0.3

0.3

Color key
0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0
a

Each heat map cell indicates the percentage of CpG sites positive for methylation. Blue corresponds to low methylation and red to high methylation according to color key shown below the table.
CpG site number specifies the specific base pair location of the CpG site in relation to the first base pair of the first exon.
c
Number shown is the total number of reads associated with each amplicon for each sample.
d
Sequencing of this amplicon failed for the samples indicated.
b
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TABLE 5
Average Methylation per CpG Site for the Mgmt Promoter Region Sequenced by Roche 454 a
CpG Site Number b
Number
reads c

13

37

48

62

77

88

106

111

113

124

137

181

187

206

218

229

235

237

243

248

Normal

23

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

3.6

0.0

0.0

0.0

5.0

0.0

0.0

0.0

3.6

0.0

0.0

0.0

15w

Normal

950

0.0

1.7

4.6

1.2

0.0

1.0

1.2

0.2

0.4

0.8

1.3

0.2

1.8

0.3

1.1

1.3

1.9

0.9

1.2

1.3

Sham

25w

Normal

1239

1.4

0.8

1.1

0.8

1.7

1.2

1.1

1.0

1.4

1.1

0.6

1.3

0.8

0.9

0.5

0.4

1.2

1.3

1.5

1.1

Sham

35w

Normal

959

0.2

1.2

0.7

1.2

3.0

0.3

0.7

0.6

0.4

0.6

0.3

1.0

0.7

0.2

0.7

0.7

0.8

1.8

0.7

0.8

Sham

45w

Normal

996

0.3

0.5

0.1

0.1

0.8

1.3

0.4

0.7

0.8

0.9

0.4

0.8

0.8

0.5

0.7

0.7

1.0

1.2

0.7

0.5

DBC

Neonate

Normal

72

1.1

0.0

1.1

0.0

0.0

0.0

1.1

0.0

1.9

1.1

4.2

0.0

0.0

1.3

0.0

0.7

1.1

0.0

0.0

0.0

BaP

Neonate

Normal

0.0

0.0

0.0

2.9

0.0

1.1

1.1

1.1

1.1

1.1

2.3

2.3

1.1

1.1

1.1

2.5

1.1

2.7

5.3

2.3

DBC

15w

Normal

61
439

0.0

0.0

0.0

0.3

0.4

0.2

0.0

0.6

0.2

0.0

0.0

0.4

0.2

0.8

0.5

0.5

0.2

0.3

0.8

0.7

DBC

25w

Normal

1014

0.7

0.5

0.6

0.7

2.9

0.5

0.4

0.9

0.7

0.6

0.4

1.6

1.5

0.8

2.1

1.2

1.5

1.7

1.5

1.4

DBC

25w

AAH

621

3.5

4.6

3.4

5.0

8.0

3.8

5.1

4.1

5.5

2.9

3.0

6.9

5.6

3.7

6.1

3.7

6.5

6.8

6.7

5.8

DBC

25w

Tumor
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2.9

3.5

4.9

4.6

6.8

3.9

4.4

4.6

4.2

3.7

0.4

4.6

4.3

1.5

1.8

4.3

4.9

4.4

4.2

5.5

DBC

35w

Normal

932

2.9

2.4

1.9

3.5

8.3

2.0

5.5

1.9

3.1

2.0

0.4

2.7

1.7

0.5

1.7

8.7

1.8

2.0

1.7

1.7

DBC

35w

AAH

827

1.7

4.3

2.3

6.2

4.8

2.3

2.2

1.8

4.8

3.1

1.1

0.8

0.7

0.9

0.8

0.6

0.6

1.2

2.0

2.0

DBC

35w

Tumor

1223

0.3

3.9

3.0

0.8

4.8

3.6

3.5

3.2

5.8

1.8

1.6

3.8

2.3

1.3

1.2

1.8

1.6

0.9

3.2

3.4

DBC

45w

Normal

0.2

0.4

0.3

0.6

0.7

0.9

1.5

1.0

2.2

1.1

0.3

0.8

0.7

0.8

0.5

0.4

0.5

1.2

1.3

0.8

DBC

45w

AAH

1183
1115

0.2

1.8

1.0

0.4

1.2

0.5

8.8

0.5

0.3

0.2

0.3

0.3

0.5

0.3

0.6

0.4

0.1

5.4

0.3

0.4

DBC

45w

Tumor

1180

11.1

12.2

11.8

10.6

3.3

7.8

7.3

7.4

10.7

2.6

6.1

4.0

3.4

0.3

2.3

2.3

1.4

3.3

9.4

8.5

Carcinogen

Age

Tissue type

Sham

Neonate

Sham

Color key
0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0
a

Each heat map cell indicates the percentage of CpG sites positive for methylation. Blue corresponds to low methylation and red to high methylation according to color key shown below the table.
CpG site number specifies the specific base pair location of the CpG site in relation to the first base pair of the first exon.
c
Number shown is the total number of reads associated with each amplicon for each sample.
b
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TABLE 6
Average Methylation per CpG Site for the Rarb Promoter Region Sequenced by Roche 454 a
CpG Site Number b
Carcinogen

Sham
Sham
Sham
Sham
Sham
DBC
BaP
DBC
DBC
DBC
DBC
DBC
DBC
DBC
DBC
DBC
DBC

Age

Neonate
15w
25w
35w
45w
Neonate
Neonate
15w
25w
25w
25w
35w
35w
35w
45w
45w
45w

Tissue type

Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
Normal
AAH
Tumor
Normal
AAH
Tumor
Normal
AAH
Tumor

Number
reads c

16

27

48

52

63

70

76

84

96

116

124

136

138

140

148

150

156

146
1520
1557
1507
1510
206
269
1079
1427
1434
1124
1473
1079
1531
1456
1463
1486

0.5
4.2
0.5
7.0
9.6
0.0
0.2
3.5
5.1
10.1
4.1
7.5
7.3
14.3
4.6
1.5
8.0

1.3
3.4
0.7
8.1
5.3
0.9
1.1
2.9
8.4
7.9
2.1
5.0
8.9
1.1
0.2
2.8
0.4

0.0
0.8
0.2
0.5
0.6
0.7
0.0
1.0
1.4
3.9
0.3
1.1
0.9
1.3
0.6
0.9
0.9

0.0
0.8
0.7
1.1
0.9
0.0
0.0
1.3
2.1
4.7
5.8
1.1
2.9
2.9
1.8
0.3
2.6

2.0
0.9
1.2
2.6
1.5
0.8
0.7
1.8
2.5
4.6
8.7
1.5
4.0
3.2
1.6
2.2
1.3

0.7
0.6
0.9
0.6
0.5
0.0
0.2
0.8
1.6
3.5
1.0
1.0
2.6
1.5
0.7
0.6
2.0

0.0
1.8
0.6
1.0
0.7
0.7
0.0
0.5
1.2
2.1
5.3
0.6
1.6
1.2
1.1
1.1
1.4

0.0
0.7
1.7
0.5
0.6
1.4
1.1
1.1
1.4
2.3
1.0
0.6
0.1
0.4
0.5
1.2
0.2

0.5
0.5
0.7
0.7
0.6
0.7
1.2
0.4
1.5
3.4
0.8
0.6
1.1
0.7
0.5
0.3
0.9

0.0
0.4
0.6
1.4
0.6
0.7
0.9
0.4
0.5
4.7
0.9
1.1
0.6
1.1
0.8
0.6
0.6

0.0
0.1
0.4
0.5
1.1
0.3
0.9
0.3
0.7
1.6
0.4
0.3
0.6
0.6
0.9
0.2
0.9

0.7
0.0
1.0
0.9
0.5
0.3
2.0
0.4
0.9
1.7
0.4
1.0
1.9
0.4
0.4
0.4
1.7

0.5
0.2
0.7
0.6
0.3
1.4
2.1
0.4
0.7
0.8
1.0
0.8
1.5
0.2
0.4
0.4
0.4

0.0
0.7
0.9
0.9
0.6
0.5
0.0
0.4
0.7
1.3
2.8
0.4
1.3
0.5
0.4
1.1
0.7

0.0
0.7
0.2
0.4
0.7
0.3
0.0
0.6
1.0
1.5
0.7
0.9
1.0
0.8
0.6
1.1
0.7

1.3
0.7
0.2
0.5
0.3
0.5
0.2
0.3
0.4
0.3
0.4
0.3
1.3
0.5
0.8
0.1
0.8

0.0
0.3
0.6
0.5
0.9
0.5
0.7
0.3
0.8
1.0
1.0
1.6
0.7
0.4
0.5
0.1
0.2

Color key
0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0
a

Each heat map cell indicates the percentage of CpG sites positive for methylation. Blue corresponds to low methylation and red to high methylation according to color key shown below the table.
CpG site number specifies the specific base pair location of the CpG site in relation to the first base pair of the first exon.
c
Number shown is the total number of reads associated with each amplicon for each sample.
b
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Overall, methylation of CpG sites in the amplicon sequenced for Cdkn2a was
minimal (<10%), with one region from sites 27 to 30 showing a moderate methylation
frequency (15 to 60 %) (Fig. 8). Results of hierarchical clustering according to animal
group showed that sham mice had a similar methylation profile, with the exception of 25
week-old sham mice, which grouped more closely with DBC-initiated offspring (Fig.
8A). When considering each individual mouse methylation pattern, no distinct clusters
were evident, likely due to the broad pattern of overall very low methylation evident
across all samples for most CpG sites (Fig. 8B).
Analysis of methylation for Dapk1 (Fig. 9) revealed that the region sequenced is
consistently unmethylated in lung tissues from all ages of offspring, with no discernible
differences among sham, DBC- or BaP-initiated mice. Cluster analysis did not reveal any
pattern in methylation for age, carcinogen treatment or tissue type for average
methylation data (Fig. 9A). Small groupings of two to three animals by tissue type, such
as 35 week DBC-initiated mice were observed in the bi-directional hierarchical clustering
of the individual mouse methylation profiles (Fig. 9B). Results for methylation analyses
of the Mgmt and Rarb amplicons was similar to that for Dapk1 in that the frequency of
methylation was very low for all the CpG sites examined, and no clear patterns emerged
from the unsupervised clustering according to offspring age, carcinogen exposure or the
type of lung tissue (Fig. 10 and 11).

FIG. 8. Methylation profile for region of Cdkn2a gene promoter by 454 deep bisulfite
sequencing. Each heat map cell indicates the percentage of CpG sites positive for
methylation. Heat map shading indicates percent methylation for each CpG site (scale bar
blue to red shown at bottom). (A) Bi-directional hierarchical clustering of the average
methylation of groups for each time point (n = 4 mice per group). Green bars indicate
sample groupings for lung tissues from sham-initiated offspring, neonates initiated with
DBC and BaP and offspring initiated with DBC at multiple time points. (B) Bidirectional hierarchical clustering of each sampled mouse individually with mice labeled
A-D for each time, tissue type. Colored boxes indicate grouping per animal for each time
point and tissue type. N, normal; H, hyperplasia; T, tumor; Neo, neonate.

A

Cdkn2a

B
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FIG. 9. Methylation profile for region of Dapk1 gene promoter by 454 deep bisulfite
sequencing. Each heat map cell indicates the percentage of CpG sites positive for
methylation. Heat map shading indicates percent methylation for each CpG site (scale bar
blue to red shown at bottom). (A) Bi-directional hierarchical clustering of the average
methylation of groups for each time point (n = 4 mice per group). Green bars indicate
sample groupings for lung tissues from sham-initiated offspring and offspring initiated
with DBC at multiple time points. (B) Bi-directional hierarchical clustering of each
sampled mouse individually with mice labeled A-D for each time, tissue type. Colored
boxes indicate grouping per animal for each time point and tissue type. N, normal; H,
hyperplasia; T, tumor; Neo, neonate.

A

Dapk1
B
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FIG. 10. Methylation profile for region of Mgmt gene promoter by 454 deep bisulfite
sequencing. Each heat map cell indicates the percentage of CpG sites positive for
methylation. Heat map shading indicates percent methylation for each CpG site (scale bar
blue to red shown at bottom). (A) Bi-directional hierarchical clustering of the average
methylation of groups for each time point (n = 4 mice per group). Green bars indicate
sample groupings for lung tissues from sham-initiated offspring, neonates initiated with
DBC and BaP and offspring initiated with DBC at multiple time points. (B) Bidirectional hierarchical clustering of each sampled mouse individually with mice labeled
A-D for each time, tissue type. Colored boxes indicate grouping per animal for each time
point and tissue type. N, normal; H, hyperplasia; T, tumor; Neo, neonate.

A

Mgmt
B
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FIG. 11. Methylation profile for region of Rarb gene promoter by 454 deep bisulfite
sequencing. Each heat map cell indicates the percentage of CpG sites positive for
methylation. Heat map shading indicates percent methylation for each CpG site (scale bar
blue to red shown at bottom). (A) Bi-directional hierarchical clustering of the average
methylation of groups for each time point (n = 4 mice per group). Green bars indicate
sample groupings for lung tissues from sham-initiated offspring, neonates initiated with
DBC and BaP and offspring initiated with DBC at multiple time points. (B) Bidirectional hierarchical clustering of each sampled mouse individually with mice labeled
A-D for each time, tissue type. Colored boxes indicate grouping per animal for each time
point and tissue type. N, normal; H, hyperplasia; T, tumor; Neo, neonate.

A

Rarb
B
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Genome-Wide Methylation Analysis
The impact of transplacental exposure to DBC and BaP on DNA methylation of
lung tumors and normal adjacent lung tissue in the adult offspring mice was assessed
utilizing NimbleGen’s genome-wide DNA methylation promoter array. The processed
array data obtained from NimbleGen are provided as calculated peak scores for all
methylation peaks detected on the array (Appendix A) (Fish, 2015a) and calculated peak
scores for peaks nearest to transcription start site (Appendix B) (Fish, 2015b). Given the
small sample size of three in individuals per tissue type, the large number of observations
and the limited range of values for peak scores, we did not expect to detect significant
differences among the treatment groups using standard statistical analysis for
microarrays. Thus, we employed a gene ontology analytical approach to determine
whether differences were evident among the biological pathways represented by
differentially methylated genes for the various lung tissue types examined, including:
normal sham, normal adjacent in DBC-initiated offspring (AdjDBC), tumor in DBCinitiated offspring (TumDBC), normal adjacent in BaP-initiated offspring (AdjBaP), and
tumor in BaP-initiated offspring (TumBaP). A summary table of peak scores for all genes
identified as methylated in any sample is provided in Table C.1 of Apendix C (Fish,
2015c), which was generated using the processed data for nearest peak scores. This
summary table was then used to generate gene lists with unique terms (e.g., methylated in
sham tissues but not in AdjDBC or TumDBC tissues) for further analysis. Gene lists for
all comparisons of interest are provided in Table E.2 of Appendix D (Fish, 2015d).
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FIG. 12. Venn diagrams depicting segregation of differentially methylated genes
among lung tissue types, as well as the number of genes similarly methylated among
groups (overlapping regions). (A) Venn diagram depicts the number of genes identified
as methylated for sham normal lung tissue, normal adjacent (AdjDBC) and tumor tissue
(TumDBC) from DBC-initiated offspring. (B) Venn diagram depicts the number of
genes identified as methylated for sham normal lung tissue, normal adjacent
(AdjBaP)and tumor tissue (TumBaP) from BaP-initiated offspring. (C) Venn diagram
depicts the number of genes identified as methylated for sham normal lung tissue and
tumor tissues from both BaP- and DBC-initiated offspring. Coloring of Venn diagrams
corresponds to colors assigned to tissue types in Tables 7-9.

Functional gene ontology (GO) analysis of differentially methylated genes for
adjacent and tumor tissue of lungs from DBC- or BaP-initiated mice and from shaminitiated mice revealed differences in the GO terms for biological processes associated
with each group. Each of the Venn diagrams (Fig. 12) depicts the number of differentially
methylated genes identified for each sample type used in the functional gene ontology
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analysis, as well as the number of genes similarly methylated among groups (overlapping
regions). This GO analysis, based on the differentially methylated gene lists of a given
comparison, reports what functions are associated with genes methylated in a select tissue
sample. For example, the analysis identifies GO terms associated with genes methylated
in sham tissues, but not methylated in tumor DBC or adjacent DBC tissues. Results of
gene ontology analysis are presented here for biological process terms only; see Tables
E.1-E.3 (Appendix E) for complete results of ontology analysis, including GO terms and
FDR values for biological process, cellular compartment and molecular function.
By populating the gene list for ontology analysis with genes that were uniquely
methylated in specific sample types (e.g., normal tissue from sham-initiated mice) or
groupings of samples (e.g., genes methylated in tumors from BaP- and DBC-initiated
mice), we were able to identify biological functions associated with promoter
hypermethylation specific to a tissue type. Table 7 and Fig. 13 depict functional gene
ontology analysis of differently methylated genes for adjacent and tumor tissues of lungs
from DBC-initiated mice and from normal lung tissue of sham-initiated mice. A total of
44 categories are represented by the comparison of the differentially methylated gene
lists. Genes in the methylated Sham list are represented in 40 of the 44 enriched GO
terms, while the methylated tumor DBC gene list is composed of 35 enriched GO terms.
Interestingly, there are only four enriched GO terms associated with the methylated genes
in the normal adjacent DBC tissue samples. The strength of enrichment is indicated by
the FDR-adjusted p-value. While 31 terms appear in both Sham and TumDBC enriched
GO term lists, it is important to note that genes that made up the comparison lists for

FIG. 13. Biological processes associated with genes differentially methylated in lung
tumors from both DBC- and BaP-initiated offspring. Gene ontology map for GO terms
representing hypermethylated gene promoters unique to lung tumor tissues from DBCand BaP-initiated offspring (not sham). Gene ontology analysis was performed using the
AgriGO singular enrichment analysis (SEA) tool (http://bioinfo.cau.edu.cn/agriGO)
against the mouse gene ontology database (Mouse Genome Informatics). Significantly
enriched GO terms (Generic GO Slim) were determined using the Fisher test with an
FDR-corrected significance level of P<0.05 (Yekutieli multi-test adjustment method) and
the minimum number of mapping entries set at 5 genes.

<0.05'

<1e$09'

FDR$p$value$

Rela*onship$

Methylated in TumDBC and TumBaP (not sham)
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GO:0044237
GO:0009987
GO:0044267
GO:0032502
GO:0051234
GO:0010467

GO:0044260

GO:0048856
GO:0009653
GO:0065007
GO:0009058
GO:0005975
GO:0007154
GO:0007049
GO:0030154
GO:0008283
GO:0044249
GO:0016043
GO:0048869
GO:0034645

GO Term

anatomical structure development
anatomical structure morphogenesis
biological regulation
biosynthetic process
carbohydrate metabolic process
cell communication
cell cycle
cell differentiation
cell proliferation
cellular biosynthetic process
cellular component organization
cellular developmental process
cellular macromolecule biosynthetic
process
cellular macromolecule metabolic
process
cellular metabolic process
cellular process
cellular protein metabolic process
developmental process
establishment of localization
gene expression

Description

82
131
28
47
40

5.40E-06
1.10E-06
1.30E-02
1.20E-04
5.60E-03

63

14
26
14
49
32
27
35

1.50E-02
1.50E-02
3.90E-02
3.80E-03
5.80E-03
1.50E-02
1.80E-02
8.80E-05

39
24
80
49
10

Num

5.00E-04
2.10E-03
1.70E-03
5.60E-03
2.80E-02

FDR

Sham

2.10E-02
2.10E-02

FDR

AdjDBC

42
66

Num

54
87
27
24
26

2.70E-03
2.70E-03
4.20E-03

36
2.90E-06
4.70E-09

2.50E-03

18
11
33
23
18
23

13

2.10E-02
7.40E-03
8.90E-03
1.60E-03
1.70E-03
1.10E-02
1.20E-02

25
13
48
33

Num

1.50E-03
3.20E-02
3.10E-03
2.10E-03

FDR

TumDBC

TABLE 7.
Functional Analysis of Differently Methylated Genes for Adjacent and Tumor Tissues of Lungs From
DBC-Initiated Mice and From Normal Lung Tissue of Sham-Initiated Mice
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GO:0019222
GO:0000003

GO:0006996
GO:0044238
GO:0019538
GO:0006464
GO:0050789
GO:0065008
GO:0050794
GO:0010468
GO:0060255

GO:0040007
GO:0006629
GO:0051179
GO:0009059
GO:0043170
GO:0043412
GO:0008152
GO:0007275
GO:0032501
GO:0006807
GO:0006139

GO Term

growth
lipid metabolic process
localization
macromolecule biosynthetic process
macromolecule metabolic process
macromolecule modification
metabolic process
multicellular organismal development
multicellular organismal process
nitrogen compound metabolic process
nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process
organelle organization
primary metabolic process
protein metabolic process
protein modification process
regulation of biological process
regulation of biological quality
regulation of cellular process
regulation of gene expression
regulation of macromolecule metabolic
process
regulation of metabolic process
reproduction

Description

5.60E-03
5.80E-03

1.80E-02
1.80E-06
2.70E-03
6.60E-04
9.40E-03
5.60E-03
2.00E-02
5.00E-04
2.00E-03

6.20E-03
1.90E-02
4.90E-06
5.00E-04
2.30E-07
4.00E-05
6.20E-03
3.60E-03
6.70E-03

FDR

Sham

38
14

19
85
36
25
69
29
64
36
37

39
35
73
26
98
46
57
46
41

Num

49
40

2.80E-03

Num

7.80E-03

FDR

AdjDBC

22

8.90E-03

27
9

40
20
38

3.10E-02
2.70E-03
3.50E-02

1.50E-03
1.40E-02

51

57
26
34
26
26

7
13
27
23
39

Num

4.50E-05

2.70E-05
2.40E-03
1.50E-02
2.50E-02
8.60E-03

3.50E-02
1.00E-03
2.30E-03
1.20E-02
2.50E-03

FDR

TumDBC
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Description

FDR

Num

FDR

AdjDBC
Num

FDR

TumDBC
Num

GO:0006350
transcription
5.80E-03
30
GO:0006810
transport
4.90E-02
31
2.70E-03
24
Note: Gene lists for functional ontology analysis were generated by selecting features with Log2 peak ratio > 2 (indicates methylated
DNA) in all three samples of interest and excluding all features that were not methylated (log2 peak ratio <2) in at least 2 of the 3
biological samples not of interest. Thus, genes in the methylated Sham list were consistently methylated in only the sham tissues. Gene
ontology was performed using AgriGO (Du, et al., 2010) using the singular enrichment analysis tool against the mouse gene ontology
database (Mouse Genome Informatics) with the following parameters: Fisher test with FDR under dependency correction and
significance level of P<0.05 and the minimum number of mapping entries set at 5 genes. The gene ontology type performed was a
generic GO slim (Gene Ontology Consortium). GO terms shown above are for biological processes; see Table E.1 for complete results
of ontology analysis, including terms for cellular compartment and molecular function. For each tissue, the FDR-adjusted P value and
the number of genes associated with the GO term are shown. Color blocks indicate the level of significance for each GO term, colorcoded according to the tissue type for cross reference with figures and supplemental materials (gray scale, Sham; blue scale, AdjDBC;
red scale, TumDBC). Absence of P value and gene numbers for a GO term indicates that that term was not significantly enriched for
that particular gene set. For clarity, in cases where a biological process is represented in more than one tissue type, the specific
methylated genes associated with that term are different for each tissue.

GO Term

Sham

52
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performing the GO analysis were entirely unique. Furthermore, this analysis does not
discern the regulatory function of the genes in the lists, but can facilitate the exploration
of biological meaning in higher order pathways and the inter-relationships between terms.
Within this comparison (Sham vs. AdjDBC and TumDBC), methylated genes were overrepresented in biological function categories unique to normal lung tissue of shaminitiated mice include cell cycle (FDR = 1.50E-02), regulation of gene expression (FDR =
5.00E-04), transcription (FDR = 5.80E-03) and protein modification process (FDR =
6.60E-04), among others. Genes methylated in tumor tissue from DBC-initiated mice
were over-represented in biological function categories cell communication (FDR =
2.10E-02) and growth (FDR = 3.50E-02).
Fig. 14 and Table 8 show the results of functional analysis of differently
methylated genes for adjacent and tumor tissues of lungs from BaP-initiated mice and
from normal lung tissue of sham-initiated mice. A total of 40 enriched GO terms are
represented, of which 36 are associated with the genes methylated in tumor BaP samples,
20 are associated with genes methylated in normal adjacent BaP tissue, and only 6 GO
terms are over-represented from genes methylated in normal lung tissue of sham-initiated
mice. The higher number of enriched categories for tumor BaP suggests that the
methylation profile associated with tumor BaP is more functionally diverse than that of
either normal adjacent BaP or Sham profiles. Tumor tissue from BaP-initiated mice
yielded a methylation profile enriched for genes associated with cell-cell signaling (FDR
= 1.10E-02), cellular developmental process (FDR = 4.0E-03) and translation (FDR =
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Methylated in Sham (not TumDBC or TumBaP)

FDR$p$value$

Rela*onship$

<1e$09'

<0.05'

FIG. 14. Biological processes associated with genes differentially methylated in
normal lung tissue from sham-initiated offspring. Gene Ontology map for GO terms
representing hypermethylated gene promoters unique to sham tissues (not methylated in
lung tumors from DBC- or BaP-initiated offspring). Gene ontology analysis was
performed using the AgriGO singular enrichment analysis (SEA) tool
(http://bioinfo.cau.edu.cn/agriGO) against the mouse gene ontology database (Mouse
Genome Informatics). Significantly enriched GO terms (Generic GO Slim) were
determined using the Fisher test with an FDR-corrected significance level of P<0.05
(Yekutieli multi-test adjustment method) and the minimum number of mapping entries
set at 5 genes.

anatomical structure development
anatomical structure morphogenesis
biological regulation
biosynthetic process
carbohydrate metabolic process
cell communication
cell differentiation
cell proliferation
cell-cell signaling
cellular amino acid and derivative
metabolic process
cellular biosynthetic process
cellular developmental process
cellular macromolecule biosynthetic
process
cellular macromolecule metabolic
process
cellular metabolic process
cellular process
cellular protein metabolic process
developmental process
establishment of localization

GO:0048856
GO:0009653
GO:0065007
GO:0009058
GO:0005975
GO:0007154
GO:0030154
GO:0008283
GO:0007267
GO:0006519

GO:0044237
GO:0009987
GO:0044267
GO:0032502
GO:0051234

GO:0044260

GO:0044249
GO:0048869
GO:0034645

Description

GO Term

27

12

3.90E-02

3.90E-02

26
22

Num

7.50E-03
5.10E-05

FDR

Sham

2.00E-02

23

53
79

24

2.10E-02

3.10E-05
4.90E-05

36

3.60E-04

8

17

3.80E-02

2.80E-03

36
8

Num

5.50E-04
2.10E-02

FDR

Adjacent BaP

8.40E-05
1.00E-09
1.30E-02
6.00E-05
8.40E-05

6.20E-04

8.40E-05
4.00E-03
6.20E-04

2.60E-06
5.00E-05
2.40E-04
5.30E-05
2.30E-02
2.40E-04
2.20E-03
2.00E-02
1.10E-02

FDR

65
119
24
41
36

50

47
25
35

40
25
70
49
9
22
25
13
10

Num

Tumor BaP

Functional Analysis of Differently Methylated Genes for Adjacent and Tumor Tissues of
Lungs From BaP-Initiated Mice and From Normal Lung Tissue of Sham-Initiated Mice

TABLE 8

55

55

Description

FDR

Num

FDR

Num

Adjacent BaP
FDR

Num

Tumor BaP

establishment of protein localization
2.50E-02
10
homeostatic process
2.20E-02
12
lipid metabolic process
3.30E-04
14
2.30E-02
12
localization
3.70E-02
24
4.90E-05
41
macromolecule biosynthetic process
2.10E-02
24
1.50E-04
37
macromolecule localization
2.50E-02
12
macromolecule metabolic process
5.10E-05
59
metabolic process
3.90E-02
50
3.10E-05
59
4.60E-07
82
multicellular organismal
3.90E-02
25
5.50E-05
39
development
GO:0032501 multicellular organismal process
2.30E-04
43
2.30E-03
50
GO:0006807 nitrogen compound metabolic
8.20E-03
30
1.70E-02
36
process
GO:0044238 primary metabolic process
2.40E-05
55
1.10E-05
70
GO:0019538 protein metabolic process
3.70E-03
30
GO:0050789 regulation of biological process
1.20E-03
62
GO:0065008 regulation of biological quality
1.70E-02
23
GO:0050794 regulation of cellular process
2.90E-03
58
GO:0060255 regulation of macromolecule
9.10E-03
29
metabolic process
GO:0019222 regulation of metabolic process
6.60E-03
32
GO:0050896 response to stimulus
4.00E-02
22
GO:0006412 translation
8.00E-03
10
GO:0006810 transport
2.00E-02
23
8.40E-05
36
Note: Gene lists for functional ontology analysis were generated by selecting features with Log2 peak ratio > 2 (indicates methylated
DNA) in all three samples of interest and excluding all features that were not methylated (log2 peak ratio <2) in at least 2 of the 3

GO:0045184
GO:0042592
GO:0006629
GO:0051179
GO:0009059
GO:0033036
GO:0043170
GO:0008152
GO:0007275

GO Term

Sham

56

56

biological samples not of interest. Thus, genes in the methylated Sham list were consistently methylated in only the sham tissues. Gene ontology
was performed using AgriGO (Du, et al., 2010) using the singular enrichment analysis tool against the mouse gene ontology database (Mouse
Genome Informatics) with the following parameters: Fisher test with FDR under dependency correction and significance level of P<0.05 and the
minimum number of mapping entries set at 5 genes. The gene ontology type performed was a generic GO slim (Gene Ontology Consortium). GO
terms shown above are for biological processes; see Table E.2 for complete results of ontology analysis, including terms for cellular compartment
and molecular function. For each tissue, the FDR-adjusted P value and the number of genes associated with the GO term are shown. Color blocks
indicate the level of significance for each GO term, color-coded according to the tissue type for cross reference with Figures and supplemental
materials (gray scale, Sham; green scale, AdjBAP; orange scale, TumBAP). Absence of P value and gene numbers for a GO term indicates that
that term was not significantly enriched for that particular gene set. For clarity, in cases where a biological process is represented in more than one
tissue type, the specific methylated genes associated with that term are different for each tissue.
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57
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8.0E-03) GO terms, among other processes unique to the list. Both normal lung tissue of
sham-initiated mice and tumor tissue of lungs from BaP-initiated mice yielded
methylation profiles enriched for genes associated with the cell proliferation GO term
(FDR = 3.90E-02, 2.0E-02, respectively).
Fig. 15 and Table 9 depict functional analysis of differently methylated genes for
tumor tissues obtained from lungs of DBC- and/or BaP-initiated mice and from normal
lung tissue of sham-initiated mice. The enriched GO terms represented by all four
comparison groups methylated gene lists total 42, with normal lung tissue from shaminitiated mice containing the most functionally diverse list of genes. In addition to Table
5, Fig. 13-15 provide graphical representations of the enriched GO terms for each of the
different tissue types compared. Normal lung tissue of sham-initiated mice yielded the
most functionally diverse methylation profile enriched for genes in sham (not TumDBC
or TumBaP) (Fig. 14) associated with embryonic development (FDR = 3.50E-02), cell
proliferation (FDR = 1.80E-02), cell differentiation (FDR = 3.60E-03), gene expression
(FDR = 1.30E-03) and transcription (FDR = 2.10E-03) among the total 37 biological
processes represented in the list. The least functionally diverse or most uniform gene list
within this comparison was of tumor tissue from DBC-initiated mice. The TumDBC (not
sham or TumBaP) methylation gene list was associated with only five enriched pathways
(Fig. 15). The functional diversity between the lists of tumor BaP and tumor DBC plus
BaP does not seem to differ much when based on the number of enriched pathways
represented by each list, 20 and 22, respectively. However, there is diversity between the
two lists as only ten of the 22 enriched GO terms for tumor DBC plus BaP are similarly
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A

Methylated in TumDBC
(not sham or TumBaP)

FDR$p$value$

B

Rela*onship$

<1e$09'

<0.05'

FIG. 15. Biological processes associated with genes differentially methylated in lung
tumor for either DBC- or BaP initiated offspring. (A) GO map for GO terms representing
hypermethylated gene promoters unique to tumor tissues from DBC-initiated mice (not
methylated in sham lung tissue or lung tumors from BaP-initiated offspring). (B) GO map
for GO terms representing hypermethylated gene promoters unique to tumor tissues from
BaP-initiated mice (not methylated in sham lung tissue or lung tumors from DBCinitiated offspring). Gene ontology analysis was performed using the AgriGO singular
enrichment analysis (SEA) tool (http://bioinfo.cau.edu.cn/agriGO) against the mouse
gene ontology database (Mouse Genome Informatics). Significantly enriched GO terms
(Generic GO Slim) were determined using the Fisher test with an FDR-corrected
significance level of P<0.05 (Yekutieli multi-test adjustment method) and the minimum
number of mapping entries set at 5 genes.

Methylated in TumBaP (not sham or TumDBC)

anatomical structure
development
anatomical structure
morphogenesis
biological regulation
biosynthetic process
cell communication
cell differentiation
cell proliferation
cellular biosynthetic
process
cellular component
organization
cellular developmental
process
cellular macromolecule
biosynthetic process
cellular macromolecule
metabolic process
cellular metabolic process
cellular process
cellular protein metabolic
process

GO:0048856

GO:0044237
GO:0009987
GO:0044267

GO:0044260

GO:0034645

GO:0048869

GO:0016043

GO:0065007
GO:0009058
GO:0007154
GO:0030154
GO:0008283
GO:0044249

GO:0009653

Description

GO Term

2.10E-04
4.70E-08
3.50E-02

3.90E-04

1.90E-03

1.90E-03

69
124
24

55

36

28

32

26
14
44

3.60E-03
1.80E-02
4.70E-03
1.10E-03

72
44

28

40

N

1.90E-03
7.10E-03

1.20E-05

2.10E-05

FDR

Sham

4.90E-04
5.20E-05

FDR

42
67

N

Tumor DBC

2.00E-02
1.40E-05

40
77

17

15
17

5.60E-03
2.00E-02

2.90E-02

43

16

22

N

3.70E-02

3.60E-03

1.20E-02

FDR

Tumor BaP

1.30E-03
1.30E-03

2.70E-03

1.40E-03

1.30E-03

1.40E-03

6.80E-03

1.30E-03

FDR

32
48

25

19

24

24

11

19

N

Tumor DBC + BaP

Functional Analysis of Differently Methylated Genes for Tumor Tissues Obtained From Lungs of
DBC- or BaP-Initiated Mice and From Normal Lung Tissue of Sham-Initiated Mice

TABLE 9
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cytoskeleton organization
developmental process
embryonic development
establishment of
localization
gene expression
homeostatic process
localization
macromolecule
biosynthetic process
macromolecule metabolic
process
macromolecule
modification
metabolic process
multicellular organismal
development
multicellular organismal
process
nitrogen compound
metabolic process
nucleobase, nucleoside,
nucleotide and nucleic
acid metabolic process
organelle organization
primary metabolic process
protein metabolic process

GO:0007010
GO:0032502
GO:0009790
GO:0051234

GO:0006996
GO:0044238
GO:0019538

GO:0006139

GO:0006807

GO:0032501

GO:0008152
GO:0007275

GO:0043412

GO:0043170

GO:0010467
GO:0042592
GO:0051179
GO:0009059

Description

GO Term

2.70E-03
3.50E-05
7.30E-03

8.70E-03

5.00E-03

9.20E-04

2.70E-06
4.00E-05

2.20E-02

20
73
31

37

41

56

86
42

19

66

35
36

8.70E-03
2.10E-03
1.20E-05

39

8
45
12

N

1.30E-03

3.00E-02
3.50E-05
3.50E-02

FDR

Sham

1.50E-04

5.20E-05

FDR

44

50

N

Tumor DBC

3.00E-04
2.00E-02

4.80E-02

7.10E-05
2.00E-02

2.30E-03

48
21

32

55
23

39

10
27

25

2.10E-03

2.00E-02
2.30E-03

24

N

2.20E-02

FDR

Tumor BaP

1.40E-03

5.20E-03

6.40E-03

2.70E-02

1.30E-03
1.30E-03

1.40E-03

1.40E-03

2.80E-03

1.30E-03

FDR

32

19

20

23

37
20

28

19

19

21

N

Tumor DBC + BaP

61

61

Description

FDR

N

FDR

N

Tumor DBC
FDR

Tumor BaP
N

FDR

N

Tumor DBC + BaP

protein modification
3.00E-02
18
process
GO:0050789 regulation of biological
5.10E-03
64
4.80E-02 39
process
GO:0050794 regulation of cellular
2.30E-02
58
process
GO:0010468 regulation of gene
4.00E-05
36
2.50E-03
16
expression
GO:0060255 regulation of
2.10E-04
37
2.80E-03
17
macromolecule metabolic
process
GO:0019222 regulation of metabolic
8.10E-04
38
1.40E-03
19
process
GO:0000003 reproduction
2.10E-02
9
GO:0006350 transcription
2.10E-03
29
1.40E-03
16
GO:0006810 transport
2.10E-03 25
Note: Gene lists for functional ontology analysis were generated by selecting features with Log2 peak ratio > 2 (indicates methylated
DNA) in all three samples of interest and excluding all features that were not methylated (log2 peak ratio <2) in at least 2 of the 3
biological samples not of interest. Thus, genes in the methylated Sham list were consistently methylated in only the sham tissues. Gene
ontology was performed using AgriGO (Du, et al., 2010) using the singular enrichment analysis tool against the mouse gene ontology
database (Mouse Genome Informatics) with the following parameters: Fisher test with FDR under dependency correction and
significance level of P<0.05 and the minimum number of mapping entries set at 5 genes. The gene ontology type performed was a
generic GO slim (Gene Ontology Consortium). GO terms shown above are for biological processes; see Table E.3 for complete results
of ontology analysis, including terms for cellular compartment and molecular function. For each tissue, the FDR-adjusted P value and
the number of genes associated with the GO term are shown. Color blocks indicate the level of significance for each GO term, colorcoded according to the tissue type for cross reference with Figures and supplemental materials (gray scale, Sham; red scale, TumDBC;
orange scale, TumBaP; light blue scale, union set for both TumDBC and TumBaP). Absence of P value and gene numbers for a GO
term indicates that that term was not significantly enriched for that particular gene set. For clarity, in cases where a biological process is
represented in more than one tissue type, the specific methylated genes associated with that term are different for each tissue.

GO:0006464

GO Term

Sham

62

62

63
enriched within the tumor BaP gene list. Again, it is important to note that genes that
made up the comparison lists for performing the GO analysis were entirely unique. GO
terms enriched by hypermethylated gene promoters for lung tumor tissues from DBCand BaP-initiated offspring (not sham) (Fig. 13) were nucleobase, nucleoside, nucleotide
and nucleic acid metabolic process (FDR = 5.20E-03), regulation of gene expression
(FDR = 2.50E-03), gene expression (FDR = 2.80E-03) and transcription (FDR = 1.40E03), among the twelve pathways not similarly enriched for the BaP gene list. Tumor
tissue from BaP-initiated mice yielded a methylation profile enriched for genes in
TumBaP (not sham or TumDBC) (Fig. 15) associated with cell differentiation (FDR =
2.0E-02), cell communication (FDR = 5.60E-03), transport (FDR = 2.10E-03) and
homeostatic process (FDR = 2.0E-02) among other biological processes. See Fig. F.1F.10 in Appendix F (Fish, 2015e) for GO maps of other comparisons among tissue types
using gene lists provided in Appendix D (Fish, 2015d). In summary, this gene ontology
analysis showed that transplacental PAH exposure altered biological pathways associated
with the regulation and control of many critical processes involved in lung tumorigenesis.
Ten genes were selected for further post-hoc inspection based on observations
from the DNA methylation array and their relevance to tumorigenesis, including Bcl2l11,
Bmp1, Fgfr1op, Hoxb1, Pdcd4, Casp7, Il11, Pten, Maea, and Tpd52l1. For each of these
genes, the peak score data were aligned with sequence information to inspect patterns of
methylation across all sample types using SignalMap software. Interestingly, for some
genes selected for post-hoc inspection, the NimbleGen-predicted CpG island did not
overlap with the identified region(s) of high methylation according to the array data. In
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addition, EMBOSS Cpgplot (Li, et al., 2015) was used as an independent prediction tool
to confirm CpG islands for the selected genes. The Cpgplot-predicted CpG islands
coincided with the NimbleGen-predicted CpG island for each gene. Furthermore, for
several genes the Cpgplot-prediction revealed additional smaller CpG islands located
apart from the NimbleGen-predicted CpG island. However, this observed discrepancy
does not necessarily extend to all genes identified as differentially methylated using the
NimbleGen platform, as additional random inspection showed good alignment (data not
shown). The Bmp1 gene promoter genomic DNA was clearly hypermethylated in sham
lung tissues, as a large region spanning about 2400 bp of methylation had peak scores
above the 2.0 threshold (Fig. 16). This methylation pattern was consistent for all
individuals in the sham group and was also very similar to the methylation pattern
evident for normal adjacent lung tissues obtained from DBC- or BaP-initiated mice.
Alternatively, methylation was largely absent in this region in tumor tissues obtained
from DBC- or BaP-exposed offspring, save for two small regions of hypermethylation in
one animal in the TumBaP group (Fig. 16). Similarly, the gene promoter genomic DNA
for Fgfr1op (Fig. 17) was methylated in all sham lung tissue and adjacent normal tissues
obtained from DBC- or BaP-initiated mice. Yet no tumor tissue samples had methylation
surpassing the threshold score (a −log10 p-value > 2). A related pattern was observed for
the Hoxb1 promoter, for which all individuals in the sham group were similar to the
methylation pattern evident for normal adjacent lung tissues (Fig. 18). Interestingly,
within the tiled region of Hoxb1, there were two regions of methylation separated by

FIG. 16. Methylation of Bmp1 promoter in normal and tumor lung tissues. This figure
illustrates methylation profiles for the promoter region of Bmp1 obtained using the
NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq Promoter Array.
Chromosomal location, predicted CpG islands (black) and tiled regions are all mapped
according to the NCBI37/mm9 mouse genome assembly. Also, CpG islands predicted by
EMBOSS Cpgplot are shown in purple. Tracks representing control samples are shown in
grey, adjacent normal DBC samples as blue, tumor DBC samples as red, adjacent normal
BaP as green and tracks for tumor BaP as orange. Each sample is represented by two
tracks, the peak scores and threshold score >2.0. The threshold score >2.0 track
visualizes, by means of the solid bar, the region of peak scores that have surpassed the
significance threshold and are thus considered to be hypermethylated. The peak score
track displays the resulting score for each probe calculated as -log10 p-value using the
one-sided Kolmogorov-Smirnov test.
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FIG. 17. Methylation of Fgfr1op promoter in normal and tumor lung tissues. This
figure illustrates methylation profiles for the promoter region of Fgfr1op obtained using
the NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq Promoter
Array. Chromosomal location, predicted CpG islands (black) and tiled regions are all
mapped according to the NCBI37/mm9 mouse genome assembly. Also, CpG islands
predicted by EMBOSS Cpgplot are shown in purple. Tracks representing control samples
are shown in grey, adjacent normal DBC samples as blue, tumor DBC samples as red,
adjacent normal BaP as green and tracks for tumor BaP as orange. Each sample is
represented by two tracks, the peak scores and threshold score >2.0. The threshold score
>2.0 track visualizes, by means of the solid bar, the region of peak scores that have
surpassed the significance threshold and are thus considered to be hypermethylated. The
peak score track displays the resulting score for each probe calculated as -log10 p-value
using the one-sided Kolmogorov-Smirnov test.
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FIG. 18. Methylation of Hoxb1 promoter in normal and tumor lung tissues. This
figure illustrates methylation profiles for the promoter region of Hoxb1 obtained using
the NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq Promoter
Array. Chromosomal location, predicted CpG islands (black) and tiled regions are all
mapped according to the NCBI37/mm9 mouse genome assembly. Also, CpG islands
predicted by EMBOSS Cpgplot are shown in purple. Tracks representing control samples
are shown in grey, adjacent normal DBC samples as blue, tumor DBC samples as red,
adjacent normal BaP as green and tracks for tumor BaP as orange. Each sample is
represented by two tracks, the peak scores and threshold score >2.0. The threshold score
>2.0 track visualizes, by means of the solid bar, the region of peak scores that have
surpassed the significance threshold and are thus considered to be hypermethylated. The
peak score track displays the resulting score for each probe calculated as -log10 p-value
using the one-sided Kolmogorov-Smirnov test.
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about 1,600 bps, for both the sham group and the adjacent normal tissues obtained from
DBC-initiated mice.
In contrast, the methylation pattern across sample types was entirely different for
Bcl2l11, which was highly methylated in all tumor samples and had relatively no
methylation of adjacent normal or sham samples (Fig. 19). The methylated regions for
Bcl2l11 ranged from 500 bp to 1500 bp, and all but one BaP tumor sample were
hypermethylated within the same 1700 bp span (location Chr2: 127949400-127951100).
A similar pattern was observed for the Pdcd4 promoter, for which hypermethylation was
evident for a short region (approximately 400 bp) in TumDBC tissue and a region of
varying length (400 to 1200 bp) in TumBaP tissues (Fig 20). The Pdcd4 gene promoter
was mostly not methylated in normal adjacent lung tissues and sham tissues. A related
methylation pattern for Pten was observed, for which methylation peaks were evident
within all the DBC-initiated tumor samples (Fig. 21). A major difference was observed in
that methylation was largely absent from the BaP-exposed offspring. The Pten gene
promoter was mostly not methylated in normal adjacent lung tissues and sham tissues.
For both Casp7 (Fig 22) and IL11 (Fig 23) gene promoters, the methylation
pattern was consistent for all the sham tissue samples with methylation peak scores above
the 2.0 threshold for regions of about 200 to 600bp in length. While some methylation
was apparent in other tissue types, none of the peak score values for those samples
exceeded the threshold indicating hypermethylation.

FIG. 19. Methylation of Bcl2l11 promoter in normal and tumor lung tissues. This
figure illustrates methylation profiles for the promoter region of Bcl2l11 obtained using
the NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq Promoter
Array. Chromosomal location, predicted CpG islands (black) and tiled regions are all
mapped according to the NCBI37/mm9 mouse genome assembly. Also, CpG islands
predicted by EMBOSS Cpgplot are shown in purple. Tracks representing control samples
are shown in grey, adjacent normal DBC samples as blue, tumor DBC samples as red,
adjacent normal BaP as green and tracks for tumor BaP as orange. Each sample is
represented by two tracks, the peak scores and threshold score >2.0. The threshold score
>2.0 track visualizes, by means of the solid bar, the region of peak scores that have
surpassed the significance threshold and are thus considered to be hypermethylated. The
peak score track displays the resulting score for each probe calculated as -log10 p-value
using the one-sided Kolmogorov-Smirnov test.
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FIG. 20. Methylation of Pdcd4 promoter in normal and tumor lung tissues. This figure
illustrates methylation profiles for the promoter region of Pdcd4 obtained using the
NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq Promoter Array.
Chromosomal location, predicted CpG islands (black) and tiled regions are all mapped
according to the NCBI37/mm9 mouse genome assembly. Also, CpG islands predicted by
EMBOSS Cpgplot are shown in purple. Tracks representing control samples are shown in
grey, adjacent normal DBC samples as blue, tumor DBC samples as red, adjacent normal
BaP as green and tracks for tumor BaP as orange. Each sample is represented by two
tracks, the peak scores and threshold score >2.0. The threshold score >2.0 track
visualizes, by means of the solid bar, the region of peak scores that have surpassed the
significance threshold and are thus considered to be hypermethylated. The peak score
track displays the resulting score for each probe calculated as -log10 p-value using the
one-sided Kolmogorov-Smirnov test.
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FIG. 21. Methylation of Pten promoter in normal and tumor lung tissues. This figure
illustrates methylation profiles for the promoter region of Pten obtained using the
NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq Promoter Array.
Chromosomal location, predicted CpG islands (black) and tiled regions are all mapped
according to the NCBI37/mm9 mouse genome assembly. Also, CpG islands predicted by
EMBOSS Cpgplot are shown in purple. Tracks representing control samples are shown in
grey, adjacent normal DBC samples as blue, tumor DBC samples as red, adjacent normal
BaP as green and tracks for tumor BaP as orange. Each sample is represented by two
tracks, the peak scores and threshold score >2.0. The threshold score >2.0 track
visualizes, by means of the solid bar, the region of peak scores that have surpassed the
significance threshold and are thus considered to be hypermethylated. The peak score
track displays the resulting score for each probe calculated as -log10 p-value using the
one-sided Kolmogorov-Smirnov test.
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FIG. 22. Methylation of Casp7 promoter in normal and tumor lung tissues. This figure
illustrates methylation profiles for the promoter region of Casp7 obtained using the
NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq Promoter Array.
Chromosomal location, predicted CpG islands (black) and tiled regions are all mapped
according to the NCBI37/mm9 mouse genome assembly. Also, CpG islands predicted by
EMBOSS Cpgplot are shown in purple. Tracks representing control samples are shown in
grey, adjacent normal DBC samples as blue, tumor DBC samples as red, adjacent normal
BaP as green and tracks for tumor BaP as orange. Each sample is represented by two
tracks, the peak scores and threshold score >2.0. The threshold score >2.0 track
visualizes, by means of the solid bar, the region of peak scores that have surpassed the
significance threshold and are thus considered to be hypermethylated. The peak score
track displays the resulting score for each probe calculated as -log10 p-value using the
one-sided Kolmogorov-Smirnov test.
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FIG. 23. Methylation of Il11 promoter in normal and tumor lung tissues. This figure
illustrates methylation profiles for the promoter region of Il11 obtained using the
NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq Promoter Array.
Chromosomal location, predicted CpG islands (black) and tiled regions are all mapped
according to the NCBI37/mm9 mouse genome assembly. Also, CpG islands predicted by
EMBOSS Cpgplot are shown in purple. Tracks representing control samples are shown in
grey, adjacent normal DBC samples as blue, tumor DBC samples as red, adjacent normal
BaP as green and tracks for tumor BaP as orange. Each sample is represented by two
tracks, the peak scores and threshold score >2.0. The threshold score >2.0 track
visualizes, by means of the solid bar, the region of peak scores that have surpassed the
significance threshold and are thus considered to be hypermethylated. The peak score
track displays the resulting score for each probe calculated as -log10 p-value using the
one-sided Kolmogorov-Smirnov test.
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The promoter methylation pattern for the oncogene Maea was consistent in sham
lung tissues across all individuals, as peak scores exceeded the 2.0 threshold for a region
of approximately 1,000 bp (Fig 24). Smaller regions (200 to 400 bp) of hypermethylation
were observed in one adjacent normal DBC sample, two adjacent normal BaP samples
and one BaP tumor sample. All the methylated regions across all samples types for Maea
range fell within the same 1,200 bp span (location Chr5: 33675200-33676400). Similarly,
the Tpd52l1 gene promoter genomic DNA was methylated in all sham lung tissues, one
normal adjacent BaP sample and two BaP tumor samples (Fig 25). Alternatively,
methylation was mostly absent from the adjacent normal and DBC lung tumor tissue
samples. In addition, all the methylated peaks of Tpd52l1’s promoter were in the same
area within the tiled region (location Chr10: 31166600-31167900).
Methylation patterns obtained from the Nimblgen genome-wide array were
compared to profiles obtained by 454 amplicon sequencing for Cdkn2a, Dapk1, Mgmt
and Rarb. According to the methylation profile obtained by the array, the Cdkn2a gene
promoter was hypermethylated in one of three sham normal lung samples, two of three
tumor samples and one of three in the normal adjacent tissues for both carcinogen
initiated groups (Fig. 26). The gene promoter DNA for Dapk1 was methylated across
nearly all sample types, with methylated regions varying in length from 100 bp to 1300
bp (Fig. 27). In contrast, the methylation pattern was markedly different for both Mgmt
and Rarb. Some methylation was noted for the Mgmt promoter in two of the three sham
normal tissues, but no significant methylation in any tissues from PAH-initiated animals
(Fig. 28). Conversely, the Rarb gene promoter was devoid of any methylation in all

FIG. 24. Methylation of Maea promoter in normal and tumor lung tissues. This figure
illustrates methylation profiles for the promoter region of Maea obtained using the
NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq Promoter Array.
Chromosomal location, predicted CpG islands (black) and tiled regions are all mapped
according to the NCBI37/mm9 mouse genome assembly. Also, CpG islands predicted by
EMBOSS Cpgplot are shown in purple. Tracks representing control samples are shown in
grey, adjacent normal DBC samples as blue, tumor DBC samples as red, adjacent normal
BaP as green and tracks for tumor BaP as orange. Each sample is represented by two
tracks, the peak scores and threshold score >2.0. The threshold score >2.0 track
visualizes, by means of the solid bar, the region of peak scores that have surpassed the
significance threshold and are thus considered to be hypermethylated. The peak score
track displays the resulting score for each probe calculated as -log10 p-value using the
one-sided Kolmogorov-Smirnov test.
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FIG. 25. Methylation of Tpd52l1 promoter in normal and tumor lung tissues. This
figure illustrates methylation profiles for the promoter region of Tpd52l1 obtained using
the NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq Promoter
Array. Chromosomal location, predicted CpG islands (black) and tiled regions are all
mapped according to the NCBI37/mm9 mouse genome assembly. Also, CpG islands
predicted by EMBOSS Cpgplot are shown in purple. Tracks representing control samples
are shown in grey, adjacent normal DBC samples as blue, tumor DBC samples as red,
adjacent normal BaP as green and tracks for tumor BaP as orange. Each sample is
represented by two tracks, the peak scores and threshold score >2.0. The threshold score
>2.0 track visualizes, by means of the solid bar, the region of peak scores that have
surpassed the significance threshold and are thus considered to be hypermethylated. The
peak score track displays the resulting score for each probe calculated as -log10 p-value
using the one-sided Kolmogorov-Smirnov test.
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FIG. 26. Methylation of Cdkn2a promoter in normal and tumor lung tissues. This
figure illustrates methylation profiles for the promoter region of Cdkn2a obtained using
the NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq Promoter
Array. Chromosomal location, predicted CpG islands (black) and tiled regions are all
mapped according to the NCBI37/mm9 mouse genome assembly. Also, CpG islands
predicted by EMBOSS Cpgplot are shown in purple. Tracks representing control samples
are shown in grey, adjacent normal DBC samples as blue, tumor DBC samples as red,
adjacent normal BaP as green and tracks for tumor BaP as orange. Bright pink indicates
the region of this gene analyzed by bisulfite amplicon sequencing by 454 (data shown in
Fig. 8). Each sample is represented by two tracks, the peak scores and threshold score
>2.0. The threshold score >2.0 track visualizes, by means of the solid bar, the region of
peak scores that have surpassed the significance threshold and are thus considered to be
hypermethylated. The peak score track displays the resulting score for each probe
calculated as -log10 p-value using the one-sided Kolmogorov-Smirnov test.
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FIG. 27. Methylation of Dapk1 promoter in normal and tumor lung tissues. This
figure illustrates methylation profiles for the promoter region of Dapk1 obtained using
the NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq Promoter
Array. Chromosomal location, predicted CpG islands and tiled regions are all mapped
according to the NCBI37/mm9 mouse genome assembly. Also, CpG islands predicted by
EMBOSS Cpgplot are shown in purple. Bright pink indicates the region of this gene
analyzed by bisulfite amplicon sequencing by 454 (data shown in Fig. 9). Tracks
representing control samples are shown in grey, adjacent normal DBC samples as blue,
tumor DBC samples as red, adjacent normal BaP as green and tracks for tumor BaP as
orange. Each sample is represented by two tracks, the peak scores and threshold score
>2.0. The threshold score >2.0 track visualizes, by means of the solid bar, the region of
peak scores that have surpassed the significance threshold and are thus considered to be
hypermethylated. The peak score track displays the resulting score for each probe
calculated as -log10 p-value using the one-sided Kolmogorov-Smirnov test.
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FIG. 28. Methylation of Mgmt promoter in normal and tumor lung tissues. This figure
illustrates methylation profiles for the promoter region of Mgmt obtained using the
NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq Promoter Array.
Chromosomal location, predicted CpG islands and tiled regions are all mapped according
to the NCBI37/mm9 mouse genome assembly. Also, CpG islands predicted by EMBOSS
Cpgplot are shown in purple. Bright pink indicates the region of this gene analyzed by
bisulfite amplicon sequencing by 454 (data shown in Fig. 10). Tracks representing
control samples are shown in grey, adjacent normal DBC samples as blue, tumor DBC
samples as red, adjacent normal BaP as green and tracks for tumor BaP as orange. Each
sample is represented by two tracks, the peak scores and threshold score >2.0. The
threshold score >2.0 track visualizes, by means of the solid bar, the region of peak scores
that have surpassed the significance threshold and are thus considered to be
hypermethylated. The peak score track displays the resulting score for each probe
calculated as -log10 p-value using the one-sided Kolmogorov-Smirnov test.
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sample types (Fig. 29). Unfortunately, none of the regions for which differential
methylation was observed using the genome-wide array aligned with the region analyzed
by 454 sequencing, even though CpG islands were targeted for the ultra-deep sequencing
analysis

FIG. 29. Methylation of Rarb promoter in normal and tumor lung tissues. This figure
illustrates methylation profiles for the promoter region of Rarb obtained using the
NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq Promoter Array.
Chromosomal location, predicted CpG islands and tiled regions are all mapped according
to the NCBI37/mm9 mouse genome assembly. Also, CpG islands predicted by EMBOSS
Cpgplot are shown in purple. Bright pink indicates the region of this gene analyzed by
bisulfite amplicon sequencing by 454 (data shown in Fig. 11). Tracks representing
control samples are shown in grey, adjacent normal DBC samples as blue, tumor DBC
samples as red, adjacent normal BaP as green and tracks for tumor BaP as orange. Each
sample is represented by two tracks, the peak scores and threshold score >2.0. The
threshold score >2.0 track visualizes, by means of the solid bar, the region of peak scores
that have surpassed the significance threshold and are thus considered to be
hypermethylated. The peak score track displays the resulting score for each probe
calculated as -log10 p-value using the one-sided Kolmogorov-Smirnov test.
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DISCUSSION
This study is the first to profile genome-wide DNA promoter methylation in lung
tissues of mice exposed to environmental PAH carcinogens. Two different methodologies
were employed in the investigation of promoter methylation in normal and tumor lung
tissues from offspring exposed in utero to the environmental carcinogens DBC or BaP.
Targeted gene promoter amplicon analysis revealed consistent low methylation within the
regions sequenced for all four target genes. The genome-wide assessment of CpG island
promoter methylation revealed distinct patterns of methylation associated with normal
and adenocarcinoma lung tissues. Gene ontology analysis revealed differences in the
biological functions represented by the methylated genes in normal lung tissues
compared to tumor tissues, such as cell proliferation, cell differentiation, cell cycle and
growth, all of which are associated with the regulation and control of critical processes
involved in lung tumorigenesis. These observations contribute to the growing knowledge
that gene promoter methylation is a highly coordinated epigenetic event that is critical for
the initiation and progression of lung cancer (Belinsky, 2015).
The genome-wide assessment of DNA methylation in the present model
identified a methylation signature for lung tumorigenesis in PAH-exposed mice. A
methylation profile was evident that distinguished normal lung tissue from tumor tissue
obtained from mice initiated with either PAH carcinogen. Moreover, distinctions in DNA
methylation were also evident when contrasting methylation profiles for tumors obtained
from DBC- or BaP-initiated offspring. These distinctions were observed at the level of
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specific genes as well as in the higher order analysis of enriched GO pathways. Venn
diagram analysis identified cohorts of genes uniquely methylated in tumor tissues from
DBC-initiated (125 genes) or BaP-initiated (142 genes), as well as those genes that
shared a pattern of hypermethylation (92 genes). The enriched GO pathways represented
by gene lists from lung tumor tissue obtained from DBC- or BaP-exposed offspring
(Table 9) demonstrate the differences in methylation for these exposures. Altogether,
these data provide new knowledge that exposure to specific PAHs, though similar in
ultimate phenotypic effect, can lead to unique epigenetic profiles in lung tumors in adult
offspring.
The utilization of the two methodologies employed in the present study, genomewide and targeted amplicon methylation analysis, can lead to further functional or
biological analyses of the disease state. Bisulfite amplicon sequencing provides a rich
data set with CpG site-specific resolution for a small targeted region, approximately 300
bp. Thus, researchers must have prior knowledge or reasonable expectation that the gene
targets will be differentially methylated in the assayed tissue. One may rely on evidence
from the literature to select target genes for amplicon analyses, as in the case for this
study. Alternatively, this prior knowledge may be gained from other methylation analysis
methods, such as a genome-wide methylation array, which yields a massive amount of
data useful for discovering new target genes of interest. The genome-wide methylation
array may also reveal patterns of methylation between groups and provide information
for use in higher order gene ontology pathway analysis. However, the use of microarrays
as a first-line approach has limitations, notably with respect to their high cost, which
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necessitates limited experiment design. Furthermore, array analyses do not provide CpG
site-specific data, rather a relative score indicative of methylation for a region of about 50
bp. When these two approaches are used in conjunction, researchers may be able to better
understand the significance of the methylation profiles and their biological impact.
Based on the results obtained from analysis of the genome-wide DNA
methylation data, we identified ten genes of interest for more in-depth examination of
their role in carcinogenesis and evidence for methylation in lung cancer or other cancers
in human or animal models. These genes include Bcl2l11, Bmp1, Fgfr1op, Hoxb1, Pdcd4,
Casp7, IL11, Pten, Maea, and Tpd52l1. One should note that these genes are not
necessarily representative of genome-wide methylation patterns for any particular tissue
or disease state, and their selection was subjective in nature.
Bcl-2-like protein 11 (Bcl2l11) belongs to the Bcl-2 protein family of proapoptotic genes. In this study, the promoter region of Bcl2l11 was hypermethylated in
lung tumors of BaP- and DBC-initiated adult offspring. Others have reported that BCL2
was hypermethylated in human NSCLC with a methylation frequency of 42% (i.e., 42%
of tumors assessed had detectable levels of methylation) (Chung, et al., 2011; Zhao et al.,
2013). However, no information on methylation of Bcl2l11 in lung cancer in humans or
animal models was available prior to this research. Hypermethylation of Bcl2l11 has been
shown for other types of cancer, such as adenoid cystic carcinoma (Bell et al., 2011),
chronic myeloid leukemia with 44% methylation prevalence (San Jose-Eneriz et al.,
2009) and colon cancer with 68% promoter methylation (Cho et al., 2014). Bcl2l11 binds
to anti-apoptotic proteins, which allow the proapoptotic multidomain proteins Bax and
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Bak to form channels on the mitochondrial membrane leading to cytochrome c release
and apoptosis (Willis et al., 2007). Rahmani et al. suggested that Bcl2l11 is associated
with the disruption of kinase pathways in human leukemia cells leading to apoptotic
signaling (Rahmani et al., 2009). Moreover, Bcl2l11 was shown to be critical for
apoptosis during negative selection of autoreactive thymocytes (Bouillet et al., 2002),
mature T cells (Davey et al., 2002) and B cells (Enders et al., 2003). Also, Bcl2l11
expression controlled the proliferation rate of tumor cells (Akiyama et al., 2009). Several
researchers have obtained evidence suggesting that EGFR-driven NSCLC maintained a
survival advantage via targeting Bcl2l11 protein for proteasomal degradation through
MAPK dependent phosphorylation (Costa et al., 2007; Cragg et al., 2007; Gong et al.,
2007). Promoter hypermethylation of Bcl2l11, as seen in the present study, may be
advantageous for tumor cells as the proapoptotic function of Bcl2l11 is suppressed.
Bone morphogenetic proteins (BMP) are secreted glycoproteins belonging to the
transforming growth factor-β super family. The present study is the first to observe
hypomethylation of the Bmp1 gene promoter tissues obtained from mouse lung
adenocarcinoma in contrast with expansive regions of hypermethylation in normal
adjacent and sham lung tissues. Other BMPs were hypomethylated in cancers, such as
BMP6 in endometrial cancer (Hsu et al., 2013). Alternatively, BMP3b and BMP6 were
silenced by methylation in NSCLC (Dai et al., 2001; Dai et al., 2004; Kraunz et al.,
2005). Components of the BMP signaling cascade include protein kinases and
transcription factors belonging to the SMAD family which transduce the BMP signal to
the nucleus. The BMP gene family has been associated with an extensive range of actions

86
in cancer (Bandyopadhyay et al., 2013; Hatakeyama et al., 1997). For example,
activation of BMP signaling inhibits some cancer types, such as colorectal cancer, by
promoting growth arrest and differentiation (Blanco Calvo et al., 2009). Additionally,
abnormal BMP expression was reported in association with development and progression
of cancer of the colon, stomach, prostate and lungs (Dai, et al., 2001; Dai, et al., 2004;
Horvath et al., 2004; Kodach et al., 2008; Wen et al., 2006). Bone morphogenetic protein
1 is known to induce cartilage and bone formation and is a contributor to cell
differentiation. In this study, Bmp1 gene promoter regions exhibited a substantial loss of
methylation in the lung tumor tissue samples in comparison to the clearly methylated
normal adjacent and sham lung tissue samples. This methylation pattern is in accordance
with a role for Bmp1 in contributing to PAH-induced tumorigenesis, possibly through
induction of cell proliferation.
A similar methylation pattern was observed for fibroblast growth factor receptor 1
oncogene partner (Fgfr1op), for which the promoter region was hypermethylated in
normal and normal adjacent tissues but not methylated in tumor tissues from DBC- or
BaP-initiated mice. To our knowledge, this report is the first to examine methylation of
Fgfr1op in lung cancer. Cortese et al. (2008) observed hypermethylation in lung cancer
samples for other members of the FGFR family, such as Fgfr3, which was methylated in
100% of sampled lung adenocarcinomas and 70% of squamous cell carcinomas.
Moreover, Fgfr1 was associated with hypomethylation in Rhabdomyosarcoma tumors in
all samples tested (Goldstein et al., 2007). Fgfr1op is a fusion partner of Fgfr1 (Popovici
et al., 1999), and this chimeric protein induces myeloproliferative disease in both humans
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and mice (Guasch et al., 2004; Vizmanos et al., 2004). Gene ontology annotations related
to Fgfr1op include organelle organization, localization, protein localization and
macromolecular localization. Over-expression of FGFR1OP may contribute to the
malignancy of human lung cancer by reduced ABL1-dependant phosphorylation of
WRNIP1, resulting in cell cycle progression of lung tumors (Mano et al., 2007). A prosurvival effect of Fgfr1 has been observed in diverse cancer cells, including leukemia,
melanoma and bladder cancer (Feng et al., 2015). In the present study, the pattern of gene
promoter methylation observed fit with the presumed oncogenic function of Fgfr1op.
Homeobox B1 (Hoxb1) belongs to the homeobox (HOX) family of genes. The
methylation pattern found in this study for Hoxb1 revealed the promoter region was
hypermethylated in normal sham and normal adjacent tissues, but not methylated in
tumor tissues from DBC- or BaP-initiated mice. Interestingly, Hoxb1 was
hypermethylated in downstream regions of the human A549 lung cancer cells, while
several other HOX genes were hypermethylated in the promoter regions (Rauch et al.,
2007). Furthermore, promoter hypermethylation silenced Hoxb1 in acute myeloid
leukemia cells, with the hypermethylated fraction of the CpG island being 68 – 97%
higher in respect to normal cells (Petrini et al., 2013). In addition, researchers showed
Hoxb1 to have increased methylation levels in pituitary adenomas (Duong et al., 2012)
and oral squamous cell carcinoma with a mean frequency of promoter hypermethylation
of 98% (Xavier et al., 2014). HOX genes encode transcription factors that are defined by
the DNA-binding domain known as homeodomain (Gehring et al., 1994). In addition to
their roles in development and stem cell differentiation, HOX genes are frequently
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deregulated in several different cancers including cancers of the colon, bladder, kidney,
breast, prostate, thyroid, ovarian, melanoma and lung (Bhatlekar et al., 2014). AbateShen defined three categories of homeobox gene expression in tumor malignancy (AbateShen, 2002). In the first, homeobox genes that are normally only active during embryonic
development are re-expressed in the neoplastic cells. This first category accounts for
most cases of aberrant HOX gene expression (Abate-Shen, 2002). In the second category,
homeobox genes can be expressed in malignant cells derived from tissue in which a
particular gene is not expressed during embryogenesis. In the third category, homeobox
genes can be down-regulated in malignant cells derived from tissues in which a particular
gene is normally expressed in the fully differentiated state. When compared to AbateShen’s three categories, the present study’s methylation pattern for Hoxb1 is most similar
to the first category of homeobox gene expression. However, the pattern of aberrant
expression of specific HOX genes tends to differ based on tissue type and tumor site, and
consequently, more research is needed to elucidate the role Hoxb1 plays in lung cancer.
The methylation profile observed from the present study of programmed cell
death 4 (Pdcd4) gene promoter DNA was hypermethylated in the lung tumor samples
compared to control. No other evidence for Pdcd4 methylation in lung cancer has been
shown to date. However, 5’ CpG island methylation at the transcription start site of
PDCD4 blocks expression at the mRNA level in human glioma cell lines (Gao et al.,
2009). PDCD4 was also hypermethylated in the gene promoter of 36% of human gastric
cancer samples (Cao et al., 2012). Pdcd4 encodes a nuclear/cytoplasmic phosphoprotein
which modulates the transcription of specific genes by affecting the activity of certain
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transcription factors. Pdcd4, described as a tumor suppressor, promotes cell apoptosis,
reduces tumorigenesis and inhibits cellular invasion (Lankat-Buttgereit and Goke, 2009).
Thus, Pdcd4 down-regulation is an unfavorable prognosis in lung, colon, esophageal,
ovarian and brain cancer (Chen et al., 2003; Fassan et al., 2010; Gao, et al., 2009;
Mudduluru et al., 2007; Wei et al., 2009). Down regulation of Pdcd4 may contribute to
tumor development in at least two ways. Decreased Pdcd4 expression increases mobility
and invasiveness of tumor cells (Asangani et al., 2008; Leupold et al., 2007; Wang et al.,
2008) and deregulates the cell response to DNA damage (Bitomsky et al., 2008; Singh et
al., 2009). Hypermethylation of a gene promoter region, such as Pdcd4 in the present
study, is typically correlated with down regulation of tumor suppressor gene expression
which may be a contributing factor in carcinogenesis, as discussed above.
In this study, the Caspase-7 (Casp7) gene promoter was hypermethylated in only
the normal lung tissue of sham animals. While limited data are available on the
methylation profiles of caspase genes, Hopkins-Donaldson et al. showed that caspase-8
was methylated in 52% of small cell lung cancers and none of the NSCLC samples
(2003). Furthermore, Teitz et al. (2000) found that caspase-8 was highly methylated in
neuroblastomas. Caspase-7 is an apoptosis-related cysteine peptidase and belongs to a
family of cysteine proteases that participate in apoptotic and inflammatory signaling
pathways (Fiandalo and Kyprianou, 2012). Because of the comparable specificities of
caspases, these proteins may have some functional redundancy in vitro (Luthi and Martin,
2007). However, caspases have been shown to display distinct activities in vivo (Slee et
al., 2001), which may be explained by a compensatory mechanism (Zheng et al., 2000).
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Caspase-7, along with caspase-3, is responsible for the execution of the apoptosis
program through cleavage of caspase-activated DNase (Larsen et al., 2010). Caspase-7
and -3 are downstream targets for caspase-9, which becomes catalytically active
following formation of the apoptosome (Ohtsuka et al., 2003). If caspase-9 is inactive,
then the downstream executioner caspases’ activation is inhibited (Janssen et al., 2007).
Additionally, caspase-8 is activated during apoptosis induction and cleaves caspase-7 and
-3, leading towards apoptosis (Yuan and Kroemer, 2010). There is relatively little
evidence to support a central role for a single caspase in tumorigenesis, rather, caspases
may perform their functions jointly resulting in the combined effect of all caspases
(Olsson and Zhivotovsky, 2011). The promoter methylation profile for Casp7 pointed to
a loss of methylation in tumor tissues from PAH-initiated animals initiated samples,
further research is needed to fully elucidate the role of Casp7 in lung tumorigenesis.
In this study, the promoter region of interleukin 11 (Il11) was hypermethylated in
normal lung tissue of sham-initiated adult offspring. While methylation of IL11 in lung
cancer has not been investigated to date, researchers studying major depressive disorder
reported that the average CpG site methylation frequency was low in blood samples,
ranging from 1%-9% (Powell et al., 2013). Furthermore, other interleukins have been
shown to be methylated in lung cancer, such as IL12RB2 with methylation evident in
42% of primary NSCLCs (Suzuki et al., 2007). An interplay between genetic variants and
DNA methylation of IL13 was shown to influence asthma-related lung function (Patil et
al., 2013). Il11 is a multifunctional cytokine that directly stimulates the proliferation of
hematopoietic stem cells. Il11 plays a role in regulating cell proliferation, transcription,
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cell-cell signaling, gene expression and establishment of localization. Il11 signaling has
been associated with growth of osteosarcoma (Lewis et al., 2009) and is thought to
facilitate cell motility in human chondrosarcoma cells (Li et al., 2012b). Multiple
researchers established that Il11 plays a key role in the metastasis of breast cancer to
bone (Ren et al., 2013; Ren et al., 2014; Sotiriou et al., 2001). Furthermore, Il11 has been
shown to be an important factor mediating the proliferation and invasion of human
colorectal cancer (Chua et al., 2013; Yamazumi et al., 2006). Along with previously
mentioned cancers, Il11 expression is associated with cervical, pancreatic, prostate and
liver cancers (Ernst and Putoczki, 2014). Thus, the low methylation observed for
Il11gene promoter in the PAH-exposed offspring suggests an involvement in lung cancer
development, possibly through induction of cell proliferation.
In the present study, the promoter region of phosphatase and tensin homolog
(Pten) gene was hypermethylated in the lung tissues obtained from mice initiated with
DBC in utero. Differences observed between DBC- and BaP-initiated tissue samples may
be reflective of the different potency of these PAH compounds, as DBC is a more potent
mutagen with a higher rate of DNA adduct formation. Methylation of Pten has previously
been identified in lung cancer with 35% prevalence in NSCLC samples and 69%
prevalence among the NSCLC cell lines tested (Li et al., 2012a; Maeda et al., 2015; Soria
et al., 2002). Additionally, hypermethylation of the Pten promoter region has been
reported in numerous cancer types, such as breast cancer with a 48% methylation
prevalence (Garcia et al., 2004), glioblastomas (Wiencke et al., 2007), gastric cancer with
73% methylation prevalence (Kang et al., 2002) and endometrial cancer with 19%
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methylation prevalence (Salvesen et al., 2001). Pten is an important tumor suppressor
gene that acts through its phosphatase protein as a regulator of the cellular
phosphoinositide 3-kinase signaling pathway. This pathway regulates a wide range of
important biological processes. Thus, it is unsurprising that dysregulation of this
signaling pathway plays a key role in several different disease states (Leslie and Downes,
2004). Gene ontology annotations related to Pten include gene expression, cell
communication, response to stimulus, cell differentiation and cell death, among several
others. Pten is the most frequently mutated gene in prostate cancer, yet mutation of Pten
is rarely observed in lung cancer (9%) (Chu and Tarnawski, 2004). Methylation is
considered the main factor contributing to low expression of Pten in NSCLC cells (Soria,
et al., 2002).
This study was the first to determine a methylation profile for macrophage
erythroblast attacher (Maea) in lung cancer, and to our knowledge, no other data are
available describing the methylation status of Maea in other cancers. Maea, also known
as EMP (erythroblast macrophage protein) or human lung cancer oncogene 10 protein,
has been commonly associated with erythroblast/macrophage interactions during
erythroid differentiation and enucleation of erythroblasts (Hanspal et al., 1998; Mohandas
and Chasis, 2010; Soni et al., 2008). Moreover, Maea undergoes dynamic rearrangements
that may be involved in cytokinesis and cell division (Bala et al., 2006). In addition,
Maea is widely distributed in nonerythroid cells, such as heart, placenta, brain, liver,
kidney, pancreas, skeletal muscle and lung (Hanspal, et al., 1998). Gene ontology
annotations associated with Maea include cell cycle, regulation of biological quality
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control, cell differentiation, cytoskeleton organization and organelle organization. The
observed low methylation profile of PAH-exposed lung tissue samples for Maea, as seen
in the present study, suggest that this gene may contribute to cancer development in
DBC-initiated offspring.
The present study is the first to observe a methylation profile for tumor protein
D52-like 1 (Tpd52l1) in lung cancer. The promoter region of Tpd52l1 was consistently
hypermethylated in lung tissue obtained from all sham-initiated offspring,
hypomethylated in all tissues from DBC-initiated animals and intermittently methylated
in BaP-initiated mice. Tpd52l1 is a member of the tumor protein D52 (Tpd52) family and
is involved in cell proliferation and calcium signaling. Byrne et al. (1995) identified the
first D52-like gene, after which the Tpd52 family was identified to be contributors in
several human cancers including breast cancer (Boutros and Byrne, 2005), colon cancer
(Malek et al., 2002), ovarian cancer (Byrne et al., 2005), prostate cancer (Wang et al.,
2004), glioma (Wang et al., 2014), melanoma (Roesch et al., 2007), and lung cancer
(Chen et al., 1996). Loss of methylation of the Tpd52l1 promoter, as observed in DBCexposed offspring, may promote growth of tumor cells as loss of methylation allows for
Tpd52l1 to increase proliferation.
The four target genes selected for gene promoter amplicon analysis were selected
based on prior knowledge from the literature (see Table 1). Methylation analysis of four
genes (Cdkn2a, Rarb, Dapk1 and Mgmt) using 454 deep bisulfite sequencing of CpG
sites at single base pair resolution on targeted regions within the promoter CpG island
revealed consistent low levels of methylation within all four genes. A conserved region of
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hypermethylation in Cdkn2a amplicon was detected across all sample types, covering
four CpG sites from bp -156 to -169 upstream in relation to the first bp of the first exon.
Although interesting, the biological significance of the elevated methylation at this
location has yet to be determined. Furthermore, the approach taken in the present study
was an in-depth look at single base pair resolution within a targeted region of the
promoter of these four genes. Putative CpG island sites of the promoter regions varied in
length and number between the target genes. The CpG island within Cdkn2a was large,
beginning -1,000 bp upstream of the first exon and extending to about 300 bp
downstream. Rarb contained three separate CpG islands ranging from -300 bp to 100 bp
in relation to the first bp of the first exon. A single large CpG island surrounded Dapk1
first exon beginning at -180 bp extending to 750 bp past the first exon. Finally, the CpG
island with the promoter region of Mgmt began at -225 bp and extended to 25 bp, in
relation to the first bp of the first exon. Given the number of sample types to be examined
and the depth of sequencing desired using 454 technology, the experiment design allowed
for only one region to be sequenced per gene. Thus, it is possible that other regions of the
gene promoter were differentially methylated. Indeed, since this analysis was performed,
new cost-effective technologies have become available that would allow for more
extensive methylation analysis of the entire promoter region, while also allowing for a
large number of samples to be sequenced. Our approach aimed at CpG site-specific
methylation in an attempt to achieve a greater depth of analysis, resulting in a fine
resolution of data which can only be achieved by sequencing. In addition to the amplicon
sequencing, the four target genes methylation profiles were identified using the genome-
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wide assessment of DNA methylation, which corresponded with the low levels of
methylation observed for the sequenced regions. Interestingly, three of the four target
gene promoter regions were methylated in regions not analyzed by bisulfite sequencing.
However, the methylation patterns observed for these genes differed based on tissue type
and, consequently, the pattern of gene promoter methylation observed did not fit with the
presumed tumor suppressor function of these cancer critical genes.
Results of this study provide further supporting evidence that DBC is a
substantially more potent transplacental carcinogen when compared to BaP. Even though
BaP was administered at a substantially higher dose than DBC, lung tumor incidence was
only a fraction (29.5%) of the rate observed for DBC-initiated offspring (100%). A
similar trend was also observed for lung tumor multiplicity. Initial studies of
transplacental exposure to DBC and BaP using the cross of strain B6129SF1/J dams to
129S1/SvlmJ sires were developed by Yu et al. (2006a; 2006b). The incidence of lung
tumors in initial studies employing a single high dose was 100% and the average lung
tumor multiplicity was 13 to 15 per tumor-bearing animal (Castro, et al., 2008a; Castro,
et al., 2008b; Castro et al., 2009; Castro, et al., 2008c; Yu, et al., 2006a; Yu, et al.,
2006b). In a subsequent study, Shorey et al. (2012) developed a multiple dosing regimen
resulting in reduced gross lung tumor incidence of 80% and reduced multiplicity (3
tumors per tumor-bearing animal) in comparison to previous studies. Our gross lung
tumor data, utilizing the multiple dosing regimen, more closely resembled the outcome of
the initial single high dose studies, with 100% tumor incidence and tumor multiplicity
typically ranging from 3 to 15 tumors per tumor-bearing animal within the DBC group.
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BaP previously had never been used in a multiple dosing regimen, and lung tumor
incidence was 30% with lung tumor multiplicity at one to two tumors per tumor-bearing
animal. Although the study was not designed to compare lung tumorigenesis among
males and females, we did make an interesting observation that lung tumor incidence was
lower in BaP-initiated females than in males. Historically, lung cancer incidence is
consistently higher in men compared to women in all populations, with sex ratios varying
from about 1.5 to 20 (International Agency for Research on Cancer, 2008). Tobacco
smoke is a major risk factor for lung cancer, and gender differences in lung cancer
mortality reflect patterns of smoking uptake and cessation over time (American Cancer
Society, 2015). However, other researchers found that women may be more susceptible
to tobacco smoke and potentially more vulnerable to lung cancer (Kiyohara and Ohno,
2010). Further work is needed to understand the gender differences in susceptibility to
lung cancer.
In conclusion, we identified a set of cancer-related genes with distinct methylation
profiles according to tissue type using a genome-wide approach to assess DNA promoter
methylation tumor tissues of offspring initiated with DBC or BaP in utero in comparison
to normal lung tissue from sham-initiated offspring. These new genes of interest may be
important targets for epigenetic modification during the process of lung tumorigenesis in
animals exposed to environmental PAHs. However, it remains to be seen whether PAH
exposure directly results in their altered methylation or their methylation state is
indicative of the cancer disease state. To address this uncertainty, these newly identified
target genes may be subject to 454 sequencing analysis in the same manner as the four
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tumor suppressor genes originally selected for this study. Another future application of
the data from this work would be a comparison of the methylation profile obtained for
PAH-initiated lung tumors in mice to methylation profile for human NSCLC. Such an
analysis may provide insight into the applicability of this transplacental carcinogenesis
animal model as a model for human lung cancer with respect to epigenome modifications
that occur during lung carcinogenesis. In future bioinformatics analyses, we plan to
address these questions by comparing the methylation profile obtained in the present
study with those publicly available for human NSCLC. A greater understanding of the
epigenetic events that contribute to lung tumorigenesis may enhance approaches for lung
cancer prevention and treatment and may reduce the heavy burden of this devastating
disease.
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Appendix A
NimbleGen Processed Data Report for All Methylated Peaks.
The complete data set for all detected peaks on the NimbleGen mouse
methylation array is provided as a digital data set accessible at the DOI link in the
following reference (Fish, 2015a). The .zip archive includes 15 individual digital
Microsoft Excel documents, one for each sample hybridized to the NimbleGen mouse
methylation array. Names of the individual Excel documents are provided in Table A.1,
and these documents were named according to the sample type (Sham, AdjDBC,
TumDBC, AdjBaP and TumBaP) and replicate (A, B and C). Table A.2 provides a
description of the file content according to the spreadsheet column title.

TABLE A.1
List of File Names Included in the Archive File for Appendix A
Sham_A_553635A01_ratio_peaks_mapToFeatures_All_Peaks.xls
Sham_B_553565A03_ratio_peaks_mapToFeatures_All_Peaks.xls
Sham_C_553574A01_ratio_peaks_mapToFeatures_All_Peaks.xls
AdjDBC_A_553634A03_ratio_peaks_mapToFeatures_All_Peaks.xls
AdjDBC_B_553654A03_ratio_peaks_mapToFeatures_All_Peaks.xls
AdjDBC_C_553635A02_ratio_peaks_mapToFeatures_All_Peaks.xls
TumDBC_A_553634A01_ratio_peaks_mapToFeatures_All_Peaks.xls
TumDBC_B_553565A01_ratio_peaks_mapToFeatures_All_Peaks.xls
TumDBC_C_553653A03_ratio_peaks_mapToFeatures_All_Peaks.xls
AdjBaP_A_553653A02_ratio_peaks_mapToFeatures_All_Peaks.xls
AdjBaP_B_553653A01_ratio_peaks_mapToFeatures_All_Peaks.xls
AdjBaP_C_553565A02_ratio_peaks_mapToFeatures_All_Peaks.xls
TumBaP_A_553635A03_ratio_peaks_mapToFeatures_All_Peaks.xls
TumBaP_B_553574A03_ratio_peaks_mapToFeatures_All_Peaks.xls
TumBaP_C_554845A01_ratio_peaks_mapToFeatures_All_Peaks.xls
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TABLE A.2
Definitions of File Contents for Appendix A by Spreadsheet Column Title
Column
PEAK_ID
CHROMOSOME
PEAK_START
PEAK_END
PEAK_SCORE
FEATURE_TRACK

Description

An ID for each mapped peak
Chromosome associated with peak
First base of the peak on the chromosome
Last base of the peak on the chromosome
Average −log10 p-value for probes in the peak region
The annotation track against which peaks were mapped,
which is the transcription start site for this data set
FEATURE_STRAND
Strand of the transcript
FEATURE_START
First base of the feature on the chromosome
Note: For the transcription start site, feature size is 1;
therefore, start and end positions are the same.
FEATURE_END
Last base of the feature on the chromosome
FEATURE_TO_PEAK_ Distance from center of peak to the feature
DISTANCE
Parent
Internal identification number of the transcript from which the
transcript start site is generated
Accession
NCBI RefSeq Accession ID
Name
Gene symbol of the transcript
Description
Full gene name of the transcript
Ncbi_gene_id
NCBI Entrez GeneID of the transcript
Synonyms
Other alias symbol(s) of the transcript
attr1 (etc.)
Other available attributes for the transcript
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Appendix B
NimbleGen Processed Data Report for Nearest Methylated Peaks.
The complete data set for peaks nearest to the transcription start site on the
NimbleGen mouse methylation array is provided as a digital data set accessible at the
DOI link in the following reference (Fish, 2015b). The .zip archive includes 15 individual
digital Microsoft Excel documents, one for each sample hybridized to the NimbleGen
mouse methylation array. Names of the individual Excel documents are provided in
Table B.1, and these documents were named according to the sample type (Sham,
AdjDBC, TumDBC, AdjBaP and TumBaP) and replicate (A, B and C). Table B.2
provides a description of the file content according to the spreadsheet column title.

TABLE B.1
List of File Names Included in the Archive File for Appendix B
Sham_A_553635A01_ratio_peaks_mapToFeatures_Nearest_Peak.xls
Sham_B_553565A03_ratio_peaks_mapToFeatures_Nearest_Peak.xls
Sham_C_553574A01_ratio_peaks_mapToFeatures_Nearest_Peak.xls
AdjDBC_A_553634A03_ratio_peaks_mapToFeatures_Nearest_Peak.xls
AdjDBC_B_553654A03_ratio_peaks_mapToFeatures_Nearest_Peak.xls
AdjDBC_C_553635A02_ratio_peaks_mapToFeatures_Nearest_Peak.xls
TumDBC_A_553634A01_ratio_peaks_mapToFeatures_Nearest_Peak.xls
TumDBC_B_553565A01_ratio_peaks_mapToFeatures_Nearest_Peak.xls
TumDBC_C_553653A03_ratio_peaks_mapToFeatures_Nearest_Peak.xls
AdjBaP_A_553653A02_ratio_peaks_mapToFeatures_Nearest_Peak.xls
AdjBaP_B_553653A01_ratio_peaks_mapToFeatures_Nearest_Peak.xls
AdjBaP_C_553565A02_ratio_peaks_mapToFeatures_Nearest_Peak.xls
TumBaP_A_553635A03_ratio_peaks_mapToFeatures_Nearest_Peak.xls
TumBaP_B_553574A03_ratio_peaks_mapToFeatures_Nearest_Peak.xls
TumBaP_C_554845A01_ratio_peaks_mapToFeatures_Nearest_Peak.xls
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TABLE B.2
Definitions of File Contents for Appendix B by Spreadsheet Column Title
Column

Description

PEAK_ID
CHROMOSOME
PEAK_START
PEAK_END
PEAK_SCORE
FEATURE_TRACK

An ID for each mapped peak
Chromosome associated with peak
First base of the peak on the chromosome
Last base of the peak on the chromosome
Average −log10 p-value for probes in the peak region
The annotation track against which peaks were mapped, which
is the transcription start site for this data set
Strand of the transcript
First base of the feature on the chromosome
Note: For the transcription start site, feature size is 1; therefore,
start and end positions are the same.
Last base of the feature on the chromosome
Distance from center of peak to the feature

FEATURE_STRAND
FEATURE_START
FEATURE_END
FEATURE_TO_PEAK
_DISTANCE
Parent
Accession
Name
Description
Ncbi_gene_id
Synonyms
attr1 (etc.)

Internal identification number of the transcript from which the
transcript start site is generated
NCBI RefSeq Accession ID
Gene symbol of the transcript
Full gene name of the transcript
NCBI Entrez GeneID of the transcript
Other alias symbol(s) of the transcript
Other available attributes for the transcript
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Appendix C
Peak Scores Summary Table for All Methylated Genes in Any Data Set.
A summary table of peak scores for the nearest peak to the indicated transcript for
any peak significantly methylated (score ≥ 2.0) in any of the 15 samples analyzed are
provided as a Microsoft Excel file available at a DOI link in the following reference
(Fish, 2015c). Table C.1 provides a description of the file content according to the
spreadsheet column title.

TABLE C.1
Definitions of File Contents for Appendix C by Spreadsheet Column Title
Column

Description

MGI Gene
NCBI gene ID
Symbol
Name
Peak Score

Mouse Genome Informatics (MGI) Accession number
NCBI Entrez GeneID of the transcript
Gene symbol of the transcript
Full gene name of the transcript
Average −log10 p-value for probes in the peak region

142
Appendix D
Gene Lists for Ontology Analyses
Table D.1 indicates the specific comparisons performed to generate gene lists for
ontology analysis and the number of genes in each resulting data set. These lists are
provided as a Microsoft Excel file available at the DOI link included in the following
reference (Fish, 2015d). Within this spreadsheet, each column contains a set of gene
accession numbers (MGI accession) representing genes methylated in one (or more)
tissue type(s) and not in others according to the comparisons outlined in Table D.1.

TABLE D.1
List of Comparisons Among Tissue Types to Generate
Gene Lists for Ontology Analyses
Comparisons
Methylated in Sham but not AdjDBC or TumDBC
Methylated in AdjDBC but not Sham or TumDBC
Methylated in TumDBC but not Sham or AdjDBC
Methylated in Sham but not AdjBAP or TumBAP
Methylated in AdjBAP but not Sham or TumBAP
Methylated in TumBAP but not Sham or AdjBAP
Methylated in Sham but not TumDBC or TumBAP
Methylated in TumDBC but not Sham or TumBAP
Methylated in TumBAP but not Sham or TumDBC
Methylated in TumDBC and TumBAP but not Sham

Number of genes in list
271
147
150
160
159
218
239
127
143
93
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Results of Gene Ontology Analyses for Differentially Methylated Genes

144
TABLE E.1.
AgriGO GO Slim Results for Biological Process, Molecular Function and Cellular Compartment for Sham, AdjDBC and TumDBC Tissues
Methylated in
Sham tissues
Ontology

GO Term

Description

FDR

P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P

GO:0048856
GO:0009653
GO:0065007
GO:0009058
GO:0005975
GO:0007154
GO:0007049
GO:0030154
GO:0008283
GO:0044249
GO:0016043
GO:0048869
GO:0034645
GO:0044260
GO:0044237
GO:0009987
GO:0044267
GO:0032502
GO:0051234
GO:0010467
GO:0040007
GO:0006629
GO:0051179
GO:0009059
GO:0043170
GO:0043412
GO:0008152
GO:0007275
GO:0032501
GO:0006807

5.00E-04
2.10E-03
1.70E-03
5.60E-03
2.80E-02

P

GO:0006139

anatomical structure development
anatomical structure morphogenesis
biological regulation
biosynthetic process
carbohydrate metabolic process
cell communication
cell cycle
cell differentiation
cell proliferation
cellular biosynthetic process
cellular component organization
cellular developmental process
cellular macromolecule biosynthetic process
cellular macromolecule metabolic process
cellular metabolic process
cellular process
cellular protein metabolic process
developmental process
establishment of localization
gene expression
growth
lipid metabolic process
localization
macromolecule biosynthetic process
macromolecule metabolic process
macromolecule modification
metabolic process
multicellular organismal development
multicellular organismal process
nitrogen compound metabolic process
nucleobase, nucleoside, nucleotide and nucleic acid
metabolic process

Num

Methylated in
AdjDBC tissue

Methylated in
TumDBC tissue

FDR

FDR

Num

39
24
80
49
10

1.50E-02
1.50E-02
3.90E-02
3.80E-03
5.80E-03
1.50E-02
1.80E-02
8.80E-05
5.40E-06
1.10E-06
1.30E-02
1.20E-04

14
26
14
49
32
27
35
63
82
131
28
47

5.60E-03

40

6.20E-03
1.90E-02
4.90E-06
5.00E-04
2.30E-07
4.00E-05
6.20E-03
3.60E-03

39
35
73
26
98
46
57
46

6.70E-03

41

2.10E-02
2.10E-02

42
66

7.80E-03

49

2.80E-03

40

Num

1.50E-03
3.20E-02
3.10E-03
2.10E-03

25
13
48
33

2.10E-02

13

7.40E-03
8.90E-03
1.60E-03
1.70E-03
1.10E-02
1.20E-02
2.50E-03
2.90E-06
4.70E-09

18
11
33
23
18
23
36
54
87

2.70E-03
2.70E-03
4.20E-03
3.50E-02
1.00E-03
2.30E-03
1.20E-02
2.50E-03

27
24
26
7
13
27
23
39

2.70E-05
2.40E-03
1.50E-02
2.50E-02

57
26
34
26

8.60E-03

26
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Methylated in
Sham tissues
Ontology

GO Term

Description

FDR

P
P
P
P
P
P
P
P
P
P
P
P
P
F
F
F
F
F
F
F
F
F
F
F
F
F
C
C
C
C
C
C
C
C

GO:0006996
GO:0044238
GO:0019538
GO:0006464
GO:0050789
GO:0065008
GO:0050794
GO:0010468
GO:0060255
GO:0019222
GO:0000003
GO:0006350
GO:0006810
GO:0005488
GO:0003824
GO:0043169
GO:0043167
GO:0046872
GO:0005515
GO:0003677
GO:0005509
GO:0016787
GO:0003676
GO:0000166
GO:0016773
GO:0016301
GO:0044464
GO:0005623
GO:0005622
GO:0044424
GO:0043229
GO:0043226
GO:0043231
GO:0043227

organelle organization
primary metabolic process
protein metabolic process
protein modification process
regulation of biological process
regulation of biological quality
regulation of cellular process
regulation of gene expression
regulation of macromolecule metabolic process
regulation of metabolic process
reproduction
transcription
transport
binding
catalytic activity
cation binding
ion binding
metal ion binding
protein binding
DNA binding
calcium ion binding
hydrolase activity
nucleic acid binding
nucleotide binding
phosphotransferase activity, alcohol group as acceptor
kinase activity
cell part
cell
intracellular
intracellular part
intracellular organelle
organelle
intracellular membrane-bounded organelle
membrane-bounded organelle

1.80E-02
1.80E-06
2.70E-03
6.60E-04
9.40E-03
5.60E-03
2.00E-02
5.00E-04
2.00E-03
5.60E-03
5.80E-03
5.80E-03
4.90E-02
1.50E-17
4.30E-08
4.30E-08
4.30E-08
4.30E-08
1.30E-05
1.00E-04
1.00E-04
1.70E-04
1.90E-03
5.00E-03
1.00E-02
4.10E-02
8.70E-21
8.70E-21
2.90E-15
5.30E-15
8.00E-12
8.30E-12
9.60E-11
9.60E-11

Num

19
85
36
25
69
29
64
36
37
38
14
30
31
152
76
58
58
58
73
32
15
36
37
31
14
14
190
190
141
138
117
117
105
105

Methylated in
AdjDBC tissue

Methylated in
TumDBC tissue

FDR

FDR

Num

1.20E-03
7.60E-03

66
36

8.40E-04

42

1.50E-08
1.50E-08

98
98

Num

4.50E-05

51

3.10E-02
2.70E-03
3.50E-02

40
20
38

8.90E-03
1.50E-03
1.40E-02

22
27
9

2.70E-03
4.70E-09
2.20E-05
4.00E-02
2.70E-02
3.90E-02
6.90E-03

24
83
45
24
25
24
40

8.10E-03
2.00E-02
6.90E-03

21
22
21

3.20E-13
3.20E-13
3.10E-08
3.50E-08
3.10E-08
3.10E-08
3.10E-08
3.10E-08

108
108
77
75
68
68
63
63
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Methylated in
Sham tissues
Ontology

GO Term

Description

FDR

C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
P
P
F
F
F
F
P
P
P
P
F
F
F
F
F
F

GO:0005737
GO:0044444
GO:0016020
GO:0005634
GO:0042995
GO:0005654
GO:0005783
GO:0031974
GO:0070013
GO:0043233
GO:0044446
GO:0044422
GO:0005576
GO:0031981
GO:0005773
GO:0005886
GO:0043234
GO:0044428
GO:0033036
GO:0008104
GO:0004871
GO:0004872
GO:0060089
GO:0005102
GO:0006091
GO:0007010
GO:0008219
GO:0016265
GO:0003723
GO:0005215
GO:0016740
GO:0015075
GO:0030234
GO:0022857

cytoplasm
cytoplasmic part
membrane
nucleus
cell projection
nucleoplasm
endoplasmic reticulum
membrane-enclosed lumen
intracellular organelle lumen
organelle lumen
intracellular organelle part
organelle part
extracellular region
nuclear lumen
vacuole
plasma membrane
protein complex
nuclear part
macromolecule localization
protein localization
signal transducer activity
receptor activity
molecular transducer activity
receptor binding
generation of precursor metabolites and energy
cytoskeleton organization
cell death
death
RNA binding
transporter activity
transferase activity
ion transmembrane transporter activity
enzyme regulator activity
transmembrane transporter activity

8.40E-10
5.60E-08
5.00E-05
5.80E-05
4.90E-04
1.60E-03
1.90E-03
4.30E-03
7.20E-03
7.20E-03
7.70E-03
8.80E-03
1.10E-02
1.10E-02
1.50E-02
1.60E-02
2.80E-02
4.20E-02
3.40E-02
4.10E-02

4.10E-02
4.90E-02

Num

98
67
90
59
19
12
18
15
14
14
36
36
25
12
7
37
27
15
16
14

Methylated in
AdjDBC tissue

Methylated in
TumDBC tissue

FDR

FDR

5.20E-08

2.20E-02

Num

64

17

8.40E-04
8.40E-04
8.40E-04
1.40E-02

27
26
27
10

6.40E-03
6.40E-03

14
14

Num

6.30E-05
5.70E-04
4.40E-06
3.50E-04

52
35
59
36

7.70E-03
8.40E-03
9.60E-04

23
23
19

1.90E-02

23

8.50E-03
2.30E-02
2.50E-02
2.50E-02
2.70E-02
2.70E-02

10
12
16
9
9
10

7
8
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Methylated in
Sham tissues
Ontology

F
F
F
F
C
C
C
C
C
C
C

GO Term

Description

FDR

Num

Methylated in
AdjDBC tissue

Methylated in
TumDBC tissue

FDR

FDR

Num

Num

GO:0022892
substrate-specific transporter activity
3.10E-02
10
substrate-specific transmembrane transporter activity
3.80E-02
9
GO:0022891
passive transmembrane transporter activity
4.00E-02
6
GO:0022803
GO:0015267
channel activity
4.00E-02
6
Golgi apparatus
2.70E-03
11
GO:0005794
mitochondrion
2.70E-03
16
GO:0005739
GO:0044421
extracellular region part
9.40E-03
11
proteinaceous extracellular matrix
9.80E-03
6
GO:0005578
extracellular matrix
1.50E-02
6
GO:0031012
GO:0031967
organelle envelope
4.10E-02
7
envelope
4.30E-02
7
GO:0031975
Note: Gene lists for functional ontology analysis were generated by selecting features with Log2 peak ratio > 2 (indicates methylated DNA) in all three samples of interest
and excluding all features that were not methylated (log2 peak ratio <2) in at least 2 of the 3 biological samples not of interest. Thus, genes in the methylated Sham list were
consistently methylated in only the sham tissues. Gene ontology was performed using AgriGO (Du, et al., 2010) using the singular enrichment analysis tool against the mouse
gene ontology database (Mouse Genome Informatics) with the following parameters: Fisher test with FDR under dependency correction and significance level of P<0.05 and
the minimum number of mapping entries set at 5 genes. The gene ontology type performed was a generic GO slim (Gene Ontology Consortium). GO terms shown above are for
biological processes (B), molecular function (F) and cellular component (C). For each tissue, the FDR-adjusted P value and the number of genes associated with the GO term
are shown. Color blocks indicate the level of significance for each GO term, color-coded according to the tissue type for cross reference with figures and supplemental materials
(gray scale, Sham; blue scale, AdjDBC; red scale, TumDBC). Absence of P value and gene numbers for a GO term indicates that that term was not significantly enriched for
that particular gene set. For clarity, in cases where a biological process is represented in more than one tissue type, the specific methylated genes associated with that term are
different for each tissue.
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TABLE E.2.
AgriGO GO Slim Results for Biological Process, Molecular Function and Cellular Compartment for Sham, AdjBaP and TumBaP Tissues
Methylated in Sham
tissues
Ontology

GO Term

Description

P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P

GO:0048856
GO:0009653
GO:0065007
GO:0009058
GO:0005975
GO:0007154
GO:0030154
GO:0008283
GO:0007267
GO:0006519
GO:0044249
GO:0048869
GO:0034645
GO:0044260
GO:0044237
GO:0009987
GO:0044267
GO:0032502
GO:0051234
GO:0045184
GO:0042592
GO:0006629
GO:0051179
GO:0009059
GO:0033036
GO:0043170
GO:0008152
GO:0007275
GO:0032501
GO:0006807
GO:0044238
GO:0019538

anatomical structure development
anatomical structure morphogenesis
biological regulation
biosynthetic process
carbohydrate metabolic process
cell communication
cell differentiation
cell proliferation
cell-cell signaling
cellular amino acid and derivative metabolic process
cellular biosynthetic process
cellular developmental process
cellular macromolecule biosynthetic process
cellular macromolecule metabolic process
cellular metabolic process
cellular process
cellular protein metabolic process
developmental process
establishment of localization
establishment of protein localization
homeostatic process
lipid metabolic process
localization
macromolecule biosynthetic process
macromolecule localization
macromolecule metabolic process
metabolic process
multicellular organismal development
multicellular organismal process
nitrogen compound metabolic process
primary metabolic process
protein metabolic process

FDR
7.50E-03
5.10E-05

3.90E-02

3.90E-02

Num

Methylated in
AdjBaP tissue
FDR

Num

26
22
5.50E-04
2.10E-02

36
8

3.80E-02

17

2.80E-03
3.60E-04

8
36

2.10E-02

24

3.10E-05
4.90E-05

53
79

2.00E-02
2.50E-02

23
10

12

27

3.30E-04
3.70E-02
2.10E-02
2.50E-02
3.90E-02
3.90E-02

Methylated in
TumBaP tissue

50
25

14
24
24
12

3.10E-05

59

2.30E-04
8.20E-03
2.40E-05

43
30
55

FDR

Num

2.60E-06
5.00E-05
2.40E-04
5.30E-05
2.30E-02
2.40E-04
2.20E-03
2.00E-02
1.10E-02

40
25
70
49
9
22
25
13
10

8.40E-05
4.00E-03
6.20E-04
6.20E-04
8.40E-05
1.00E-09
1.30E-02
6.00E-05
8.40E-05

47
25
35
50
65
119
24
41
36

2.20E-02
2.30E-02
4.90E-05
1.50E-04

12
12
41
37

5.10E-05
4.60E-07
5.50E-05
2.30E-03
1.70E-02
1.10E-05
3.70E-03

59
82
39
50
36
70
30
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Methylated in Sham
tissues
Ontology

GO Term

Description

P
P
P
P
P
P
P
P
F
F
F
F
F
F
F
F
F
F
F
F
F
F
C
C
C
C
C
C
C
C
C
C
C
C

GO:0050789
GO:0065008
GO:0050794
GO:0060255
GO:0019222
GO:0050896
GO:0006412
GO:0006810
GO:0005488
GO:0043169
GO:0043167
GO:0046872
GO:0003677
GO:0016788
GO:0003824
GO:0060089
GO:0004871
GO:0004872
GO:0016787
GO:0008289
GO:0005515
GO:0005215
GO:0044464
GO:0005623
GO:0005622
GO:0044424
GO:0043229
GO:0043226
GO:0005576
GO:0016020
GO:0043231
GO:0043227
GO:0005737
GO:0044444

regulation of biological process
regulation of biological quality
regulation of cellular process
regulation of macromolecule metabolic process
regulation of metabolic process
response to stimulus
translation
transport
binding
cation binding
ion binding
metal ion binding
DNA binding
hydrolase activity, acting on ester bonds
catalytic activity
molecular transducer activity
signal transducer activity
receptor activity
hydrolase activity
lipid binding
protein binding
transporter activity
cell part
cell
intracellular
intracellular part
intracellular organelle
organelle
extracellular region
membrane
intracellular membrane-bounded organelle
membrane-bounded organelle
cytoplasm
cytoplasmic part

FDR

Num

Methylated in
AdjBaP tissue
FDR

4.00E-02

3.30E-05
3.00E-03
3.00E-03
3.00E-03
4.00E-02
5.00E-02

2.80E-09
2.80E-09
5.60E-05
5.60E-05
4.10E-04
4.10E-04
1.50E-03
3.00E-03
1.20E-02
1.20E-02
2.60E-02
4.00E-02

78
30
30
30
17
9

107
107
73
72
61
61
20
54
50
50
46
31

Methylated in
TumBaP tissue

Num

FDR

Num

1.20E-03
1.70E-02
2.90E-03
9.10E-03
6.60E-03

62
23
58
29
32

8.00E-03
8.40E-05
1.70E-10

10
36
115

2.20E-04

56

4.30E-05
2.60E-03
7.00E-27
7.00E-27
3.20E-17
1.20E-15
6.70E-10
6.70E-10
1.00E-02
1.60E-12
4.40E-07
4.40E-07
8.30E-14
6.70E-10

62
18
170
170
124
119
95
95
22
96
80
80
93
62

22

2.00E-02
4.60E-06
1.10E-03
1.10E-03
1.10E-03

23
78
30
30
30

2.70E-06
1.60E-04
1.60E-04
2.10E-04
5.00E-04
3.70E-02

49
30
30
28
24
6

5.80E-11
5.80E-11
1.60E-04
1.60E-04
2.50E-03
2.50E-03

108
108
70
69
57
57

2.10E-09
3.60E-03
3.60E-03
3.30E-03
1.60E-03

70
51
51
49
36
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Methylated in Sham
tissues
Ontology
C
C
C
C
C
C
C
C
C
C
C
C
C

GO Term

Description

FDR

Num

Methylated in
AdjBaP tissue
FDR

Num

Methylated in
TumBaP tissue
FDR

Num

GO:0005886 plasma membrane
7.10E-03
26
2.90E-08
47
GO:0005794 Golgi apparatus
2.00E-02
10
GO:0005768 endosome
2.80E-02
6
GO:0005773 vacuole
3.50E-02
5
GO:0005829 cytosol
6.00E-04
13
GO:0005739 mitochondrion
1.40E-02
19
GO:0044422 organelle part
1.60E-02
30
GO:0016023 cytoplasmic membrane-bounded vesicle
2.30E-02
8
GO:0044446 intracellular organelle part
2.40E-02
29
GO:0031988 membrane-bounded vesicle
3.10E-02
8
GO:0005634 nucleus
3.70E-02
40
GO:0043232 intracellular non-membrane-bounded organelle
3.80E-02
21
GO:0043228 non-membrane-bounded organelle
3.80E-02
21
Note: Gene lists for functional ontology analysis were generated by selecting features with Log2 peak ratio > 2 (indicates methylated DNA) in all three samples
of interest and excluding all features that were not methylated (log2 peak ratio <2) in at least 2 of the 3 biological samples not of interest. Thus, genes in the
methylated Sham list were consistently methylated in only the sham tissues. Gene ontology was performed using AgriGO (Du, et al., 2010) using the singular
enrichment analysis tool against the mouse gene ontology database (Mouse Genome Informatics) with the following parameters: Fisher test with FDR under
dependency correction and significance level of P<0.05 and the minimum number of mapping entries set at 5 genes. The gene ontology type performed was a
generic GO slim (Gene Ontology Consortium). GO terms shown above are for biological processes (B), molecular function (F) and cellular component (C). For
each tissue, the FDR-adjusted P value and the number of genes associated with the GO term are shown. Color blocks indicate the level of significance for each GO
term, color-coded according to the tissue type for cross reference with Figures and supplemental materials (gray scale, Sham; green scale, AdjBAP; orange scale,
TumBAP). Absence of P value and gene numbers for a GO term indicates that that term was not significantly enriched for that particular gene set. For clarity, in
cases where a biological process is represented in more than one tissue type, the specific methylated genes associated with that term are different for each tissue.
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TABLE E.3.
AgriGO GO Slim Results for Biological Process, Molecular Function and Cellular Compartment for Sham, TumDBC and TumBaP Tissues
Methylated in Sham
tissues
Ontology
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P
P

GO Term
GO:0048856
GO:0009653
GO:0065007
GO:0009058
GO:0007154
GO:0030154
GO:0008283
GO:0044249
GO:0016043
GO:0048869
GO:0034645
GO:0044260
GO:0044237
GO:0009987
GO:0044267
GO:0007010
GO:0032502
GO:0009790
GO:0051234
GO:0010467
GO:0042592
GO:0051179
GO:0009059
GO:0043170
GO:0043412
GO:0008152
GO:0007275
GO:0032501
GO:0006807
GO:0006139
GO:0006996
GO:0044238

Description

FDR

anatomical structure development
anatomical structure morphogenesis
biological regulation
biosynthetic process
cell communication
cell differentiation
cell proliferation
cellular biosynthetic process
cellular component organization
cellular developmental process
cellular macromolecule biosynthetic process
cellular macromolecule metabolic process
cellular metabolic process
cellular process
cellular protein metabolic process
cytoskeleton organization
developmental process
embryonic development
establishment of localization
gene expression
homeostatic process
localization
macromolecule biosynthetic process
macromolecule metabolic process
macromolecule modification
metabolic process
multicellular organismal development
multicellular organismal process
nitrogen compound metabolic process
nucleobase, nucleoside, nucleotide and nucleic acid metabolic process
organelle organization
primary metabolic process

2.10E-05
1.20E-05
1.90E-03
7.10E-03

Num

Methylated in
TumBaP tissue

FDR

FDR

Num

40
28
72
44

3.60E-03
1.80E-02
4.70E-03
1.10E-03
1.90E-03
1.90E-03
3.90E-04
2.10E-04
4.70E-08
3.50E-02
3.00E-02
3.50E-05
3.50E-02

26
14
44
32
28
36
55
69
124
24
8
45
12

1.30E-03

39

8.70E-03
2.10E-03
1.20E-05
2.20E-02
2.70E-06
4.00E-05
9.20E-04
5.00E-03
8.70E-03
2.70E-03
3.50E-05

Methylated in
TumDBC tissue

35
36
66
19
86
42
56
41
37
20
73

1.20E-02
3.60E-03
3.70E-02
5.60E-03
2.00E-02

2.90E-02

4.90E-04
5.20E-05

42
67

Methylated in
TumDBC+TumBaP
tissues

Num
22
16
43

FDR

Num

1.30E-03
6.80E-03

19
11

1.40E-03

24

1.30E-03

24

19
25
32
48

15
17

17

2.00E-02
1.40E-05

40
77

1.40E-03
2.70E-03
1.30E-03
1.30E-03

2.20E-02

24

1.30E-03

21

2.10E-03

25
2.80E-03

19

1.40E-03
1.40E-03

19
28

2.00E-02
2.30E-03

10
27

2.30E-03

39

5.20E-05

50

7.10E-05
2.00E-02
4.80E-02

55
23
32

1.30E-03
1.30E-03
2.70E-02
6.40E-03
5.20E-03

37
20
23
20
19

1.50E-04

44

3.00E-04

48

1.40E-03

32
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Methylated in Sham
tissues
Ontology
P
P
P
P
P
P
P
P
P
P
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
C
C
C
C
C
C
C

GO Term
GO:0019538
GO:0006464
GO:0050789
GO:0050794
GO:0010468
GO:0060255
GO:0019222
GO:0000003
GO:0006350
GO:0006810
GO:0005488
GO:0003677
GO:0046872
GO:0003824
GO:0043169
GO:0043167
GO:0005515
GO:0003676
GO:0005509
GO:0030528
GO:0016787
GO:0003700
GO:0000166
GO:0016740
GO:0030234
GO:0008233
GO:0016772
GO:0016301
GO:0005215
GO:0044464
GO:0005623
GO:0044424
GO:0005622
GO:0043226
GO:0043229
GO:0043231

Description

FDR

protein metabolic process
protein modification process
regulation of biological process
regulation of cellular process
regulation of gene expression
regulation of macromolecule metabolic process
regulation of metabolic process
reproduction
transcription
transport
binding
DNA binding
metal ion binding
catalytic activity
cation binding
ion binding
protein binding
nucleic acid binding
calcium ion binding
transcription regulator activity
hydrolase activity
transcription factor activity
nucleotide binding
transferase activity
enzyme regulator activity
peptidase activity
transferase activity, transferring phosphorus-containing groups
kinase activity
transporter activity
cell part
cell
intracellular part
intracellular
organelle
intracellular organelle
intracellular membrane-bounded organelle

7.30E-03
3.00E-02
5.10E-03
2.30E-02
4.00E-05
2.10E-04
8.10E-04

Num

Methylated in
TumDBC tissue

Methylated in
TumBaP tissue

FDR

FDR

31
18
64
58
36
37
38
2.10E-02

2.10E-03
1.30E-12
3.10E-05
1.00E-03
1.00E-03
1.00E-03
1.00E-03
1.00E-03
1.00E-03
7.70E-03
1.00E-02
1.10E-02
4.50E-02

9.00E-18
9.00E-18
3.10E-11
3.10E-11
4.60E-08
7.30E-08
7.50E-06

Num

Methylated in
TumDBC+TumBaP
tissues

Num

2.00E-02

21

4.80E-02

39

168
168
118
120
98
97
83

Num

2.50E-03
2.80E-03
1.40E-03

16
17
19

1.40E-03

16

7.10E-03
1.20E-02

44
13

7.10E-03

17

7.10E-03

11

2.10E-02
8.90E-09
8.90E-09
2.30E-07
2.20E-07
5.10E-08
5.10E-08
2.30E-07

9
68
68
51
52
48
48
43

9

29
129
32
42
57
42
42
61
35
11
18
28
12

FDR

2.30E-11

77

2.10E-03
2.20E-07

9.80E-04
1.50E-05
6.50E-04
3.10E-04
2.30E-02

26
40
27
28
32

4.90E-02
1.00E-04
3.70E-02
3.70E-02
4.90E-03

2.00E-02

17

9.80E-04
4.00E-03
2.80E-02

20
16
8

5.80E-10
5.80E-10
1.10E-04
1.10E-04
7.00E-04
7.00E-04
3.70E-04

89
89
58
59
49
49
46

25
77
23
42
24
24
39

3.70E-02

18

3.70E-02
3.70E-02
1.30E-03
4.60E-02
4.90E-02

15
9
11
10
9

9.90E-18
9.90E-18
9.60E-10
3.90E-12
2.40E-05
2.40E-05
1.30E-04

112
112
77
83
59
59
52
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Methylated in Sham
tissues
Ontology
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C

GO Term

Description

FDR

Num

Methylated in
TumDBC tissue

Methylated in
TumBaP tissue

FDR

FDR

Num

Num

Methylated in
TumDBC+TumBaP
tissues
FDR

Num

GO:0043227
membrane-bounded organelle
7.50E-06
83
3.70E-04
46
1.30E-04
52
2.30E-07
43
GO:0005737
cytoplasm
7.60E-06
79
1.30E-03
42
4.10E-09
61
7.40E-03
31
GO:0005576
extracellular region
1.10E-05
31
3.20E-03
16
GO:0005634
nucleus
3.00E-05
55
1.50E-02
27
7.90E-05
27
GO:0044446
intracellular organelle part
1.20E-03
36
4.70E-02
18
GO:0044422
organelle part
1.40E-03
36
4.90E-02
18
GO:0016020
membrane
1.50E-03
76
1.10E-04
49
2.10E-07
61
1.80E-02
32
GO:0043232
intracellular non-membrane-bounded organelle
1.70E-03
27
GO:0043228
non-membrane-bounded organelle
1.70E-03
27
GO:0005615
extracellular space
3.10E-03
13
GO:0044444
cytoplasmic part
6.90E-03
46
1.30E-02
27
2.40E-05
38
1.80E-02
21
GO:0005694
chromosome
7.00E-03
10
GO:0044421
extracellular region part
9.60E-03
15
GO:0032991
macromolecular complex
1.30E-02
31
GO:0005856
cytoskeleton
4.60E-02
16
GO:0005886
plasma membrane
2.90E-02
20
6.10E-04
27
GO:0005794
Golgi apparatus
3.50E-02
8
GO:0016023
cytoplasmic membrane-bounded vesicle
1.50E-03
8
GO:0031988
membrane-bounded vesicle
2.20E-03
8
GO:0031410
cytoplasmic vesicle
3.50E-03
9
GO:0005829
cytosol
3.60E-03
9
GO:0031982
vesicle
5.20E-03
9
Note: Gene lists for functional ontology analysis were generated by selecting features with Log2 peak ratio > 2 (indicates methylated DNA) in all three samples of interest and excluding all features
that were not methylated (log2 peak ratio <2) in at least 2 of the 3 biological samples not of interest. Thus, genes in the methylated Sham list were consistently methylated in only the sham tissues. Gene
ontology was performed using AgriGO (Du, et al., 2010) using the singular enrichment analysis tool against the mouse gene ontology database (Mouse Genome Informatics) with the following
parameters: Fisher test with FDR under dependency correction and significance level of P<0.05 and the minimum number of mapping entries set at 5 genes. The gene ontology type performed was a
generic GO slim (Gene Ontology Consortium). GO terms shown above are for biological processes (B), molecular function (F) and cellular component (C). For each tissue, the FDR-adjusted P value
and the number of genes associated with the GO term are shown. Color blocks indicate the level of significance for each GO term, color-coded according to the tissue type for cross reference with
Figures and supplemental materials (gray scale, Sham; red scale, TumDBC; orange scale, TumBaP; light blue scale, union set for both TumDBC and TumBaP). Absence of P value and gene numbers
for a GO term indicates that that term was not significantly enriched for that particular gene set. For clarity, in cases where a biological process is represented in more than one tissue type, the specific
methylated genes associated with that term are different for each tissue.
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Appendix F
Gene Ontology Maps
Gene ontology maps were generated for all group comparisons outlined in Table
D.1.; these maps are provided as high resolution .tif files at the DOI link available in the
following reference (Fish, 2015e). This archive includes 10 individual image files (see
Table F.1), each of which depicts a Gene Ontolgoy map for GO terms representing
hypermethylated gene promoters unique for the indicated tissue(s) (listed first in file
name) compared to other tissues. Gene ontology analysis was performed using the
AgriGO singular enrichment analysis (SEA) tool (http://bioinfo.cau.edu.cn/agriGO)
against the mouse gene ontology database (Mouse Genome Informatics). Significantly
enriched GO terms (Generic GO Slim) were determined using the Fisher test with an
FDR-corrected significance level of P<0.05 (Yekutieli multi-test adjustment method) and
the minimum number of mapping entries set at 5 genes.

TABLE F.1
List of File Names Included in the Archive File for Appendix F
Figure designation

File name

Fig. F.1
Fig. F.2
Fig. F.3
Fig. F.4
Fig. F.5
Fig. F.6
Fig. F.7
Fig. F.8
Fig. F.9
Fig. F.10

GO Slim Map for Methylated in Sham, Not AdjDBC or TumDBC.tif
GO Slim Map for Methylated in AdjDBC, Not Sham or TumDBC.tif
GO Slim Map for Methylated in TumDBC, Not Sham or AdjDBC.tif
GO Slim Map for Methylated in Sham, Not AdjBaP or TumBaP.tif
GO Slim Map for Methylated in AdjBaP, Not Sham or TumBaP.tif
GO Slim Map for Methylated in TumBaP, Not Sham or AdjBaP.tif
GO Slim Map for Methylated in Sham, Not TumDBC or TumBaP.tif
GO Slim Map for Methylated in TumDBC, Not Sham or TumBaP.tif
GO Slim Map for Methylated in TumBaP, Not Sham or TumDBC.tif
GO Slim Map for Methylated in TumDBC and TumBaP, Not Sham.tif

